参考文献

参考文献

References

［1］Stanaway J D.GBD 2017 Risk Factor Collaborators,et al.Global,regional,and national comparative risk assessment of 84 behavioral,environmental and occupational,and metabolic risks or clusters of risks for 195 countries and territories,1990-2017:a systematic analysis for the global burden of disease study ［J］.Lancet,2018,392(10159):1923-1994.

［2］GBD 2017 Causes of Death Collaborators.Global,regional,and national age-sex-specific mortality for 282 causes of death in 195 countries and territories,1980-2017:a systematic analysis for the global burden of disease study 2017［J］.Lancet,2018,392(10159):1736-1788.

［3］Mills K T,Bundy J D,Kelly T N,et al.Global disparities of hypertension prevalence and control:a systematic analysis of population-based studies from 90 countries［J］.Circulation,2016,134(6):441-450.

［4］Ibrahim M M,Damasceno A.Hypertension in developing countries［J］.Lancet,2012,380(9841):611-619.

［5］Geldsetzer P,Manne-Goehler J,Marcus M E,et al.The state of hypertension care in 44 low-income and middle-income countries:a cross-sectional study of nationally representative individual-level data from 1.1 million adults［J］.Lancet,2019,394(10199):652-662.

［6］Mills K T,Stefanescu A,He J,et al.The Global Epidemiology of Hypertension［J］.Nature Reviews Nephrol,2020,16(4):223-237.

［7］Chow C K,Teo K K,Rangarajan S,et al.Prevalence,awareness,treatment,and control of hypertension in rural and urban communities in High-,Middle-,and Low-Income Countries［J］.Jama,2013,310(9):959-968.

［8］Forouzanfar M H,Liu P,Roth gA,et al.Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg,1990-2015［J］.Jama,2017,317(2):165-182.

［9］Wang Z,Chen Z,Zhang L,et al.Status of Hypertension in China:Results from the China Hypertension Survey,2012-2015［J］.Circulation,2018,137(22):2344-2356.

［10］ 《中国高血压防治指南》修订委员会.中国高血压防治指南（2018年修订版）［J］.中国心血管杂志，2019，24（1）：24-56.

［11］李立明，饶克勤，孔灵芝，等.中国居民2002年营养与健康状况调查［J］.中华流行病学杂志，2005，26（7）：478-484.

［12］Gu D,Wildman R P,Wu X,et al.Incidence and predictors of hypertension over 8 years among Chinese men and women［J］.J Hypertens,2007,25(3):517-523.

［13］胡以松，姚崇华，王文志，等.2002年中国部分民族高血压患病情况［J］.卫生研究，2006，5（5）：573-575.

［14］Lewington S,Lacey B,Clarke R,et al.The Burden of Hypertension and Associated Risk for Cardiovascular Mortality in China［J］.JAMA internal medicine,2016,176(4):524-532.

［15］Wu Y,Huxley R,Li L,et al.Prevalence,awareness,treatment,and control of hypertension in China:data from the China National Nutrition and Health Survey 2002［J］.Circulation,2008,118(25):2679-2686.

［16］范国辉，王增武，张林峰，等.2013年北方四区县农村高血压患病率、知晓率、治疗率和控制率调查［J］.中华医学杂志，2015，95（8）：616-620.

［17］Yang L,Yan J,Tang X,et al.Prevalence,Awareness,Treatment,Control and Risk Factors Associated with Hypertension among Adults in Southern China,2013［J］.Plos One,2016,11(1):e0146181.

［18］Gu H,Li W,Yang J,et al.Hypertension prevalence,awareness,treatment and control among Han and four ethnic minorities (Uygur,Hui,Mongolian and Dai) in China［J］.J Hum Hypertens,2015,29(9):555-560.

［19］Whelton P K,Carey R M,Aronow W S,et al.2017ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention,detection,evaluation,and management of high blood pressure in adults:a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines.Circulation,2018,138(17):e484-e594.

［20］Lewington S,Clarke R,Qizilbash N,et al.Age-specific relevance of usual blood pressure to vascular mortality:a meta-analysis of individual data for one million adults in 61 prospective studies［J］.Lancet,2002 360(9349):1903-1913.

［21］Guo X,Zhang X,Guo L,et al.Association between pre-hypertension and cardiovascular outcomes:a systematic review and meta-analysis of prospective studies［J］.Current Hypertension Reports,2013,15(6):703-716.

［22］Sprint R G,Wright J T Jr,Williamson J D,et al.A randomized trial of intensive versus standard bloodpressure control［J］.N Engl J Med,2015,373(22):2103-2116.

［23］Bundy J D,Li C,Stuchlik P,et al.Systolic blood pressure reduction and risk of cardiovascular disease and mortality:a systematic review and network meta-analysis［J］.Jama Cardiol,2017,2(7):775-781.

［24］Singh gM,Danaei G,Pelizzari P M,et al.The age associations of blood pressure,cholesterol,and glucose:analysis of health examination surveys from international populations［J］.Circulation,2012,125(18),2204-2211.

［25］Dorans K S,Mills K T,Liu Y,et al.Trends in prevalence and control of hypertension according to the 2017 American College of Cardiology/American Heart Association (ACC/AHA) Guideline［J］.Journal of the American Heart Association Cardiovascular & Cerebrovascular Disease,2018,7(11):e008888.

［26］Kaufman J S,Dolman L,Rushani D,et al.The contribution of genomic research to explaining racial disparities in cardiovascular disease:a systematic review［J］.Am J Epidemiol,2015,181(7):464-472.

［27］Whelton P K,Einhorn P T,Muntner P,et al.Research needs to improve hypertension treatment and control in African Americans［J］.Hypertension,2016,68(5):1066-1072.

［28］Whelton P K,He J,Appel L J,et al.Primary prevention of hypertension:clinical and public health advisory from the national high blood pressure education program［J］.Jama,2002,288(15):1882-1888.

［29］He J,Whelton P K.Salt intake,hypertension and risk of cardiovascular disease:an important public health challenge［J］.Int J Epidemiol,2002,31(2):322-327.

［30］Elliott P,Stamler J,Nichols R,et al.Intersalt revisited:further analyses of 24 hour sodium excretion and blood pressure within and across populations.Intersalt Cooperative Research Group.BMJ,1996,312(7041):1249-1253.

［31］Liu Z.Dietary sodium and the incidence of hypertension in the Chinese population:a review of nationwide surveys［J］.American Journal of Hypertension,2009,22(9):929-933.

［32］Iwahori T,Miura K,Ueshima H,et al.Urinary sodium-to-potassium ratio and intake of sodium and potassium among men and women from multiethnic general populations:the INTERSALT study［J］.Hypertens Res,2019,42(10):1590-1598.

［33］Poorolajal J,Zeraati F,Soltanian A R,et al.Oral potassium supplementation for management of essential hypertension:a meta-analysis of randomized controlled trials［J］.PLOS ONE,2017,12(4):e0174967.

［34］NCD Risk Factor Collaboration (NCD-RisC).Trends in adult body-mass index in 200 countries from 1975 to 2014:a pooled analysis of 1698 population-based measurement studies with 19.2 million participants［J］.Lancet,2016,387(10026):1377-1396.

［35］Global BMIMC,Angelantonio E D,Bhupathiraju S,et al.Body-mass index and all-cause mortality:individual-participant-data meta-analysis of 239 prospective studies in four continents［J］.Lancet,2016,388(16):776-786.

［36］Forman J P,Stampfer M J,Curhan gC,et al.Diet and lifestyle risk factors associated with incident hypertension in women［J］.Jama,2009,302(4):401-411.

［37］Manthey J,Shield K D,Rylett M,et al.Global alcohol exposure between 1990 and 2017 and forecasts until 2030:a modelling study［J］.Lancet,2019,393(10190):2493-2502.

［38］国家卫生计生委疾病预防控制局.中国居民营养与慢性病状况报告（2015）［M］.北京：人民卫生出版社，2015.

［39］Xin X,He J,Frontini M G,et al.Effects of alcohol reduction on blood pressure:a meta-analysis of randomized controlled trials［J］.Hypertension,2001,38(5):1112-1127.

［40］Guthold R,Stevens gA,Riley L M,et al.Worldwide trends in insufficient physical activity from 2001 to 2016:a pooled analysis of 358 population-based surveys with 1.9 million participants［J］.Lancet Global.Health,2018,6(10):e1077-e1086.

［41］Whelton S P,Chin A,Xin X,et al.Effect of aerobic exercise on blood pressure:a meta-analysis of randomized,controlled trials［J］.Ann Intern Med,2002,136(7):493-503.

［42］Imamura F,Micha R,Khatibzadeh S,et al.Dietary quality among men and women in 187 countries in 1990 and 2010:a systematic assessment［J］.Lancet.Glob Heal,2015,3(3):e132-e142.

［43］Appel L J,Moore T J,Obarzanek E,et al.A clinical trial of the effects of dietary patterns on blood pressure.DASHCollaborative Research Group［J］.N Engl JMed,1997,336(16):1117-1124.

［44］Yokoyama Y,Nishimura K,Barnard N D,et al.Vegetarian diets and blood pressure:a metaanalysis［J］.JAMA Internal medicine,2014,174(4):577-587.

［45］Pan Y,Cai W,Cheng Q,et al.Association between anxiety and hypertension:a systematic review and meta-analysis of epidemiological studies［J］.Neuropsychiatr Dis Treat,2015(11):1121-1130.

［46］Dong gH,Zhang B,Ke W,et al.Association between long-term air pollution and increased blood pressure and hypertension in China［J］.Hypertension,2013,61(1):578-584.

［47］Lewington S,Clarke R,Qizilbash N,et al.Age-specific relevance of usual blood pressure to vascular mortality:a meta-analysis of individual data for one million adults in 61 prospective studies［J］.Lancet,2002,360(9349):1903-1913.

［48］Anderson A H,Yang W,Townsend R R,et al.Time-updated systolic blood pressure and the progression of chronic kidney disease:a cohort study［J］.Ann Intern Med,2015,162(4):258-265.

［49］Strandberg T E,Salomaa V.White coat effect,blood pressure and mortality in men:prospective cohort study［J］.European Heart Journal,2000,21(20):1714-1718.

［50］中国高血压联盟《家庭血压监测指南》委员会.2019中国家庭血压监测指南［J］.中华高血压杂志，2019，27（8）：708-711.

［51］ 《中国高血压防治指南》修订委员会.中国高血压防治指南2018年修订版［J］.心脑血管病防治，2019，19（1）：1-44.

［52］曾春雨.高血压病学——从基础到临床、从指南到实践［M］.北京：科学出版社，2019.

［53］Bote J M,Recas J,Hermida R.Evaluation of blood pressure estimation models based on pulse arrival time［J］.Computer & Electrical Engineering,2020(84):106616.

［54］Krisai P,Vischer A S,Kilian L,et al.Accuracy of 24-hour ambulatory blood pressure monitoring by a novel cuffless device in clinical practice［J］.Heart,2019,105(5):1-7.

［55］Bilo G,Zorzi C,Ochoa Munera J E,et al.Validation of the Somnotouch-NIBP noninvasive continuous blood pressure monitor according to the European Society of Hypertension International Protocol revision 2010［J］.Blood Press Monit,2015,20(5):291-294.

［56］Gesche H,Grosskurth D,Kuchler G,et al.Continuous blood pressure measurement by using the pulse transit time:comparison to a cuff-based method［J］.Eur J Appl Physiol 2012,112(1):309-315.

［57］Omboni S,Caserini M,Coronetti C.Telemedicine and M-Health in Hypertension Management:Technologies,Applications and Clinical Evidence［J］.High Blood Press Cardiovasc Prev,2016,23(3):187-196.

［58］钱岳晟，张怡，张瑾，等.上海市普陀区高血压社区规范管理的模式和效果探讨［J］.中华高血压杂志，2012，20（1）：26-30.

［59］Williams B,Mancia G,Spiering W,et al.2018 ESC/ESH Guidelines for the management of arterial hypertension［J］.Eur Heart J,2018,39(33):3021-3104.

［60］Whelton P K,Carey R M,Aronow W S,et al.2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention,Detection,Evaluation,and Management of High Blood Pressure in Adults:Executive Summary:A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines［J］.J Am Coll Cardiol,2018,71(19):2199-2269.

［61］Ohkubo T,Kikuya M,Metoki H,et al.Prognosis of “masked”hypertension and“white-coat” hypertension detected by 24-h ambulatory blood pressure monitoring 10-year follow-up from the Ohasama study［J］.J Am Coll Cardiol,2005,46(3):508-515.

［62］Mwasongwe S,Min Y I,Booth J N,3rd,et al.Masked hypertension and kidney function decline:the Jackson Heart Study［J］.Journal of Hypertens,2018,36(7):1524-1532.

［63］Wilson P W,D’Agostino R B,Levy D,et al.Prediction of coronary heart disease using risk factor categories［J］.Circulation,1998,97(18):1837-1847.

［64］Conroy R M,Pyorala K,Fitzgerald A P,et al.Estimation of ten-year risk of fatal cardiovascular disease in Europe:the SCORE project［J］.Eur Heart J,2003,24(11):987-1003.

［65］Kusunose K,Sato M,Yamada H,et al.Prognostic Implications of Non-Invasive Vascular Function Tests in High-Risk Atherosclerosis Patients［J］.Circulation Journal of official Journal of the Japanese Circulation Society,2016,80(4):1034-1040.

［66］陈绍行，钱岳晟，张瑾，等.2种心血管病风险预测方法对社区高血压患者的危险分层评估［J］.中华高血压杂志，2011，19（4）：336-341.

［67］胡盛寿，高润霖，刘力生，等.《中国心血管病报告2018》概要［J］.中国循环杂志，2019，34（3）：209-220.

［68］Elliott W J.Clinical features and management of selected hypertensive emergencies［J］.Journal of Clinical Hypertension,2004,6(10):587-592.

［69］Erbel R,Alfonso F,Boileau C,et al.Task Force on Aortic Dissection,European Society of Cardiology Diagnosis and management of aortic dissection［J］.European Heart Journal,2001,22(18):1642-1681.

［70］Golledge J,Eagle K A.Acute aortic dissection［J］.Lancet,2008,372(9632):55-66.

［71］Wallace J D,Levy L L.Blood pressure after stroke［J］.Jama,1981,246(19):2177-2180.

［72］Grossman E,Messerli F H,Grodzicki T,et al.Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies［J］.Jama,1996,276(16):1328-1331.

［73］Broderick J,Connolly S,Feldmann E,et al .Guidelines for the management of spontaneous intracerebral hemorrhage in adults:2007 update:a guideline from the American Heart Association/American Stroke Association Stroke Council,High Blood Pressure Research Council,and the Quality of Care and Outcomes in Research Interdisciplinary Working Group ［J］.Circulation,2007,116(21):391-413.

［74］Colucci W S,Elkayam U,Horton D P,et al.Intravenous nesiritide,anatriuretic peptide in the treatment of decompensated congestive heart failure.Nesiritide Study Group［J］.New Engl J Med,2000,343(4):246-253.

［75］Hollander J E.The management of cocaine-associated myocardial ischemia［J］.N Engl J Med,1995,333(19):1267-1272.

［76］Carl J Vaughan,Norman D.Hypertensive emergencies［J］.Lancet,2000,356(9227):411-417.

［77］林果为，王吉耀，葛均波.实用内科学［M］.15 版.北京：人民卫生出版社，2017.

［78］Rimoldi S F,Scherrer U,Messerli F H.Secondary arterial hypertension:when,who,and how to screen?［J］.Eur Heart J,2014,35(19):1245-1254.

［79］郭冀珍.继发性高血压的鉴别诊断和治疗［J］.中华心血管病杂志，2004，32（s2）：13-16.

［80］Lozano L,Tovar J L,Sampol G,et al.Continuous positive airway pressure treatment in sleep apnea patients with resistant hypertension:a randomized,controlled trial［J］.J Hypertens,2010,28(10):2161-2168.

［81］Calhoun D A,Nishizaka M K,Zaman M A,et al.Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea［J］.Chest,2004,125(1):112-117.

［82］Douma S,Petidis K,Doumas M,et al.Prevalence of primary hyperaldosteronism in resistant hypertension:a retrospective observational study［J］.Lancet,2008,371(9628):1921-1926.

［83］Brown M L,Burkhart H M,Connolly H,et al.Coarctation of the aorta:lifelong surveillance is mandatory following surgical repair［J］.J Am Coll Cardiol,2013,62(11):1020-1025.

［84］Esler M.the sympathetic nervous system in hypertension:back to the future［J］.Current Hypertension Report,2015,17(2):11.

［85］Schlaich M P,Sobotka P A,Krum H,et al.Renal sympathetic-nerve ablation for uncontrolled hypertension［J］.N Engl J Med,2009,36l(9):932-934.

［86］Charron F M,Blanchard M G,Lapointe J Y.Intracellular hypertonicity isresponsible for water flux associated with Na+/glucose cotransport［J］.Biophys J,2006,90(10):3546-3554.

［87］Hiltunen T P,Hannila-Handelberg T,Petäjäniemi N,et al.Liddle’s syndrome associated with a point mutation inthe extracellular domain of the epithelial sodium channel gamma subunit［J］.Journal of Hypertens,2002,20(12):2383-2390.

［88］Navar L G,Harrison-Bernard L M,Nishiyama A,et al.Regulation of intrarenal angiotensin Ⅱin hypertension［J］.Hypertension,2002,39(2 pt 2):316-322.

［89］中国垂体腺瘤协作组.中国库欣病诊治专家共识（2015）［J］.中华医学杂志，2016，96（11）：835-840.

［90］中华医学会内分泌学分会肾上腺学组.原发性醛固酮增多症诊断治疗的专家共识［J］.中华内分泌代谢杂志，2016，32（30）：188-195.

［91］Keser G,Direskeneli H,Aksu K.Management of Takayasu arteritis:a systematic review［J］.Rheumatology,2014,53(5):793-801.

［92］Kishi T.Baroreflex failure and beat-to-beat blood pressure variation［J］.Hypertension research,2018,96(7):453-461.

［93］Robinson T G,Potter J F,Ford gA,et al.Effects of antihypertensive treatment after acute stroke in the Continue or Stop Post-Stroke Antihypertensives Collaborative Study (COSSACS):a prospective,randomised,open,blinded-endpoint trial［J］.Lancet Neurol,2010,9(8):767-775.

［94］Unger T,Borghi C,Charchar F,et al.2020 International Society of Hypertension Global Hypertension Practice Guidelines［J］.Hypertension,2020,75(6):1334-1357.

［95］国家卫生健康委员会疾病预防控制局，国家心血管病中心，中国医师协会高血压专业委员会.中国高血压健康管理规范（2019）［J］.中华心血管病杂志，2020，48（1）：10-46.

［96］Umemura S,Arima H,Arima S,et al.The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)［J］.Hypertens Res,2019,42(9):1235-1481.

［97］中国医师协会高血压专业委员会.高血压合并动脉粥样硬化防治中国专家共识［J］.中华高血压杂志，2020，28（2）：116-123.

［98］中华医学会《中华全科医师杂志》编辑委员会，心血管系统疾病基层诊疗指南编写专家组.高血压基层诊疗指南（2019年）［J］.中华全科医师杂志，2019，18（4）：301-313.

［99］中国高血压防治指南修订委员会，高血压联盟（中国），中华医学会心血管病学分会.中国高血压防治指南（2018年修订版）［J］.中国心血管杂志，2019，24（ 1 ）：24-56.

［100］Williams B,Mancia G,Spiering W,et al.2018 ESC/ESH Guidelines for the Management of Arterial Hypertension［J］.Eur Heart J,2018,39(33):3021-3104.

［101］国家卫生计生委合理用药专家委员会，中国医师协会高血压专业委员会.高血压合理用药指南（第2 版）［J］.中国医学前沿杂志（电子版），2017，9（7）：28-126.

［102］中国医师协会高血压专业委员会.钙拮抗剂/血管紧张素转换酶抑制剂单片复方制剂在高血压治疗中的应用中国专家建议［J］.中华高血压杂志，2016，24（1）：19-25.

［103］Jones N R,McCormack T,Constanti M,et al.Diagnosis and Management of Hypertension in Adults:NICE Guideline Update 2019［J］.The British Journal of General Practice,2020,70(691):90-91.

［104］2010 Atlas of chronic kidney disease and endstage renal disease in the United States.United States Renal Data System ［EB/OL］,2010.

［105］Zarif L,Covic A,Iyengar S,et al.Inaccuracy of clinical phenotyping parameters for hypertensive Nephrosclerosis［J］.Nephrol Dial Transplant,2000,15(11):1801-1807.

［106］Schlessinger S D,Tankersley M R,Curtis J J.Clinical Documentation of End-Stage Renal Disease Due to Hypertension［J］.American Journal of Kidney Disease,1994,23(5):655-660.

［107］Zucchelli P,Zuccalà A.Can We Accurately Diagnose Nephrosclerosis?［J］.Nephrol Dial Transplant,1995,10(Suppl 6):2-5.

［108］Plantinga L C,Miller E R,Stevens L A,et al.Blood Pressure Control Among Persons Without and With Chronic Kidney Disease:US Trends and Risk Factors 1999-2006［J］.Hypertension,2009,54(1):47-56.

［109］Rao M V,Qiu Y,Wang C C,et al.Hypertension and CKD:Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES),1999-2004［J］.Am J Kidney Dis,2008,51(4 Suppl 2):S30-S37.

［110］Vermeire E,Hearnshaw H,Royen P V,et al.Patient Adherence to Treatment:Three Decades of Research.A Comprehensive Review［J］.J Clin Pharm Ther,2001,26(5):331-342.

［111］Sarafidis P A,Li S,Chen S C,et al.Hypertension Awareness,Treatment,and Control in Chronic Kidney Disease［J］.Am J Med,2008,121(4):332-340.

［112］Muntner P,Anderson A,Charleston J,et al.Hypertension Awareness,Treatment,and Control in Adults With CKD:Results From the Chronic Renal Insufficiency Cohort (CRIC) Study［J］.Am J Kidney Dis,2010,55(3):441-451.

［113］彭责威，黄辉，王毅方，等.高血压非糖尿病人群高血压肾病的流行病学研究［J］.汕头大学医学院学报，2013（2）：102-105.

［114］张勉之，张敏英，沈伟梁，等.慢性肾功能衰竭原发病的流行病学研究［J］.中国慢性病预防与控制，2004，12（2）：70-72.

［115］兰雷，汪鹏，刁秀竹，等.维持性血液透析患者的临床流行病学变迁［J］.中国血液净化，2012，5（2）：53-56.

［116］张百奎，刘超.终末期肾脏疾病血液透析患者的流行病学特征［J］.江苏医药，2010（2）：62-64.

［117］龚智峰，唐盛，彭小梅，等.2006—2007年广西血液净化中心新增尿毒症血透患者流行病学分析［J］.内科，2008，3（5）：675-677.

［118］顾波，乔勤，马骏.上海市静安区行血液透析治疗的终末期肾病患者流行病学调查［J］.上海医学，2015（1）：846-850.

［119］邱艳，熊庆.低出生体重相关因素研究［J］.四川医学，2006，27（2）：123-124.

［120］周炜茹，林小明，肖金兰.197例低出生体重儿的影响因素分析［J］.中国初级卫生保健，2007，21（11）：44-46.

［121］Carlstrom M,SaUstrom J,Skott O,et al.Uninephrectomy in young age or chronic salt loading causes salt-sensitive hypertension in adult rat［J］.Hypertension,2007,49(6):1342-1350.

［122］Woods L L,Weeks D A,Rasch R.Hypertension after neonatal uninephrectomy in rats precedes glomerular damage［J］.Hypertension,2001,38(3):337-342.

［123］Hughson M,Farris A B,Douglas-Denton R.Glomerular number and size in autopsy kidneys:the relationship to birth weight［J］.Kidney Int,2003,63(6):2113-2122.

［124］Keller G,Zimmer C,Mall G.Nephron number in patients with primary hypertension［J］.New England Journal of Medicine,2003,348(2):101-108.

［125］熊友珍，王旋.高血压的危险因素及研究进展［J］.湖南环境生物职业技术学院学报，2008，14（1）：7-10.

［126］Baylis C.Sexual dimorphism of the aging kidney:role of nitric oxide deficiency［J］.Physiology (Bethesda),2008,23:142-150.

［127］Zhou X J,Rakheja D,Yu X,et al.The aging kidney［J］.Kidney Int,2008,74(6):710-720.

［128］Fliser D.The Kidneys and Old Age［J］.Dtsch Med Wochenschr,2008,133(37):1835-1838.

［129］Anderson S,Brenner B M.Effects of Aging on the Renal Glomerulus［J］.Am J Med,1986,80(3):435-442.

［130］Sullivan J C,Semprun-Prieto L,Boesen E I,et al.Sex and Sex Hormones Influence the Development of Albuminuria and Renal Macrophage Infiltration in Spontaneously Hypertensive Rats［J］.American Journal of Physiol Regul Integr Comp Physiol,2007,293(4):R1573-R1579.

［131］Sandberg K.Mechanisms Underlying Sex Differences in Progressive Renal Disease［J］.Gend Med,2008,5(1):10-23.

［132］黎磊石，刘志红.中国肾脏病学［M］.北京：人民军医出版社，2008.

［133］黎磊石，刘志红.原发性高血压的肾损害［J］.肾脏病与透析肾移植杂志，2004，13（4）：336-337.

［134］Nagase M,Matsui H,Shibata S,et al.Salt-induced Nephropathy in Obese Spontaneously Hypertensive Rats via Paradoxical Activation of the Mineralocorticoid Receptor:Role of Oxidative Stress［J］.Hypertension,2007,50(5):877-883.

［135］Tylicki L,Puttinger H,Rutkowski P,et al.Smoking as a Risk Factor for Renal Injury in Essential Hypertension［J］.Nephron Clin Pract,2006,103(4):c121-c128.

［136］刘力生.高血压发病三大危险因素［J］.心血管病防治知识，2005（5）：7-11.

［137］Bellelli G,Rozzini R,Frisoni gB,et al.Is C-reactive Protein an Independent Risk Factor for Essential Hypertension？［J］.J Hypertens,2001,19(11):2107.

［138］Sung K C,Suh J Y,Kim B S,et al.High Sensitivity C-reactive Protein as an Independent Risk Factor for Essential Hypertension［J］.Am J Hypertens,2003,16(6):429-433.

［139］胡伟，邢沈阳，李永山.C-反应蛋白及心血管危险因素对高血压交互作用［J］.中国公共卫生，2009，25（1）：9-12.

［140］Perticone F,Maio R,Sciacqua A,et al.Endothelial Dysfunction and C-reactive Protein Are Risk Factors for Diabetes in Essential Hypertension［J］.Diabetes,2008,57(1):167-171.

［141］Imatoh T,Miyazaki M,Une H.Does Elevated High-Sensitivity Serum C-reactive Protein Associate With Hypertension in Non-Obese Japanese Males？［J］.Clin Exp Hypertens,2007,29(6):395-401.

［142］Naya M,Tsukamoto T,Morita K,et al.Plasma interleukin-6 and tumor necrosis factor-alpha can predict coronary endothelial dysfunction in hypertensive patients［J］.Hypertens research,2007,30(6):541-548.

［143］Sesso H D,Wang L,Buring J E,et al.Comparison of interleukin-6 and C-reactive Protein for the Risk of Developing Hypertension in Women［J］.Hypertension,2007,49(2):304-310.

［144］Shankar A,Li J,Nieto F J,et al.Association Between C-reactive Protein Level and Peripheral Arterial Disease Among US Adults Without Cardiovascular Disease,Diabetes,or Hypertension［J］.American Heart Journal,2007,154(3):495-501.

［145］Mennuni S,Rubattu S,Pierelli G,et al.Hypertension and kidneys:unraveling complex molecular mechanisms underlying hypertensive renal damage［J］.Journal of Human Hypertension,2014,28(2):74-79.

［146］PERERA gA.Hypertensive Vascular Disease; Description and Natural History［J］.J Chronic Dis,1955,1(1):33-42.

［147］Stamler J,Wentworth D,Neaton J D.Is Relationship Between Serum Cholesterol and Risk of Premature Death From Coronary Heart Disease Continuous and Graded ？ Findings in 356,222 Primary Screenees of the Multiple Risk Factor Intervention Trial (MRFIT)［J］.Jama,1986,256(20):2823-2828.

［148］Weinberger M H.Salt Sensitivity of Blood Pressure in Humans［J］.Hypertension,1996,27(3 pt 2):481-490.

［149］刘治全.血压的盐敏感性与盐敏感性高血压［J］.高血压杂志，2005，13（3）：131-132.

［150］Weinberger M H,Miller J C,Luft F C,et al.Definitions and Characteristics of Sodium Sensitivity and Blood Pressure Resistance［J］.Hypertension,1986,8(6 pt 2):Ⅱ127-134.

［151］Lea J P,Nicholas S B.Diabetes Mellitus and Hypertension:Key Risk Factors for Kidney Disease［J］.J Natl Med Assoc,2002,94(8 Suppl):7S-15S.

［152］ Mallion J M,Baguet J P,Siché J P,et al.Clinical Value of Ambulatory Blood Pressure Monitoring ［J］.J Hypertens,1999,17(5):585-595.

［153］Liu M,Takahashi H,Morita Y,et al.Non-dipping Is a Potent Predictor of Cardiovascular Mortality and Is Associated With Autonomic Dysfunction in Haemodialysis Patients［J］.Nephrol Dial Transplant,2003,18(3):563-569.

［154］Amar J,Vernier I,Rossignol E,et al.Nocturnal Blood Pressure and 24-hour Pulse Pressure Are Potent Indicators of Mortality in Hemodialysis Patients［J］.Kidney Int,2000,57(6):2485-2491.

［155］王颖，王晋明，燕树勋.脉压与高血压性肾损害关系的临床观察［J］.中国综合临床 ，2003，19（11）：985-986.

［156］陈改玲，党爱民，刘国仗.阻塞性睡眠呼吸暂停与高血压的研究进展［J］.中国分子心脏病学杂志，2003，3（6）：382-384.

［157］Bigazzi R,Bianchi S,Batini V,et al.Metabolic Risk Factors and Markers of Cardiovascular and Renal Damage in Overweight Subjects［J］.Am J Hypertens,2006,19(4):426-431.

［158］Ribstein J,du Cailar G,Mimran A.Combined Renal Effects of Overweight and Hypertension［J］.Hypertension,1995,26(4):610-615.

［159］Tsioufis C,Tsiachris D,Dimitriadis K,et al.Evidence for No Global Effect of Metabolic Syndrome Per Se on Early Hypertensive Sequelae［J］.J Hypertens,2008,26(4):773-779.

［160］MulèG,Cottone S,Nardi E,et al.Metabolic Syndrome in Subjects With Essential Hypertension:Relationships With Subclinical Cardiovascular and Renal Damage［J］.Minerva Cardioangiol,2006,54(2):173-194.

［161］MulèG,Cerasola G.The Metabolic Syndrome and Its Relationship to Hypertensive Target Organ Damage［J］.J Clin Hypertens (Greenwich),2006,8(3):195-201.

［162］MulèG,Nardi E,Cottone S,et al.Influence of metabolic syndrome on hypertension-related target organ damage［J］.American Journal of Hypertension,2005,257(6):503-513.

［163］Caliskan M,Erdogan D,Gullu H,et al.Association Between Serum Uric Acid Levels and Coronary Flow Reserve in Hypertensive Patients Without Concomitant Risk Factors［J］.Blood Press,2007,16(4):254-261.

［164］Zoccali C,Maio R,Mallamaci F,et al.Uric Acid and Endothelial Dysfunction in Essential Hypertension［J］.J Am Soc Nephrol,2006,17(5):1466-1471.

［165］麦垚，林俊.老年原发性高血压患者高尿酸血症的肾损害［J］.中华风湿病学杂志，2005（9）：162-163.

［166］Kanellis J,Watanabe S,Li J H,et al.Uric Acid Stimulates Monocyte Chemoattractant protein-1 Production in Vascular Smooth Muscle Cells via Mitogen-Activated Protein Kinase and cyclooxygenase-2［J］.Hypertension,2003,41(6):1287-1293.

［167］Jaramillo M,Godbout M,Naccache P H,et al.Signaling Events Involved in Macrophage Chemokine Expression in Response to Monosodium Urate Crystals［J］.J Biol Chem,2004,279(50):52797-52805.

［168］Ozkan Y,Ozkan E,Simşek B.Plasma Total Homocysteine and Cysteine Levels as Cardiovascular Risk Factors in Coronary Heart Disease［J］.Int J Cardiol,2002,82(3):269-277.

［169］孙晓楠，李玉明，郭虹 .单纯收缩期高血压患者同型半胱氨酸代谢关键酶基因多态性相关因子研究［J］.中华心血管病杂志，2003，31（4）：269-270.

［170］Fogo A,Breyer J A,Smith M C,et al.Accuracy of the Diagnosis of Hypertensive Nephrosclerosis in African Americans:A Report From the African American Study of Kidney Disease (AASK) Trial.AASK Pilot Study Investigators［J］.Kidney Int,1997,51(1):244-252.

［171］Marcotoni C,Ma L T,Federspeil C,Fogo A.Hypertensive nephrosclerosis in African Americans versus Caucasians［J］.Kidney Int,2002,62(1):172-180.

［172］Olson J L.Renal disease caused by hypertension,Heptinstall’s Pathology of the Kidney,6th edition ［M］.Philadelphia,PA:Lippincott,Williams & Wilkins,2006:937.

［173］Bohle A,Ratschek M.The compensated and the decompensated form of benign nephrosclerosis［J］.Pathol Res Pract,1982,174(4):357-.367.

［174］Bohle A,Wehrmann M,Greschniok A,et al.Renal morphology inessential hypertension:Analysis of 1177 unselected cases［J］.Kidney Int,1998,54(Suppl 67):S205-S206.

［175］Hoy W E,Bertram J F,Denton R D,et al.Nephron number,glomerular volume,renal disease and hypertension［J］.Curr Opin Nephrol Hypertens,2008;17(3):358-365.

［176］Wang G,Lai F M,Kwan B C,et al.Podocyte loss in human hypertensive nephrosclerosis［J］.Am J Hypertens,2009,22(3):300-306.

［177］Sommers S C,Melamed J.Renal pathology of essential hypertension［J］.Am J Hypertens,1990,3(7):583-587.

［178］Grund K E,Mackensen S,Gruner J,et al.Renal insufficiency in nephrosclerosis (benign nephrosclerosis resp.transition from benign to secondary malignant nephrosclerosis) correlations between morphological and functional parameters［J］.Klin Wochenschr,1978,56(23):1147-1154.

［179］Fine L G,Orphanides C,Norman J T.Progressive renal disease:the chronic hypoxia hypothesis［J］.Kidney Int Suppl,1998,65:S74-S78.

［180］Ross R.The pathogenesis of atherosclerosis-an update［J］.N Engl J Med,1986,314(8):488-500.

［181］Intengan H D,Schiffrin E L.Structure and mechanical properties of resistance arteries in hypertensionrole of adhesion molecules and extracellular matrix determinants［J］.Hypertension,2000,36(3):312-318.

［182］Tracy R E,Bhandaru S Y,Oalmann M C et al.Blood pressure and nephrosclerosis in black and white men and women aged 25 to 54［J］.Mod Pathol,1991,4(5):602.

［183］Tracy R E,Malcom gT,Oalmann M C et al.Nephrosclerosis,glycohemoglobin,cholesterol and smoking in subjects dying of coronary heart disease［J］.Mod Pathol,1994,7(3):301.

［184］Tracy R E,Malcom gT,Oalmann M C,et al.Renal microvascular features of hypertension in Japan,Guatemala,and the United States［J］.Arch Pathol Lab Med,1992,116(1):50-55.

［185］Cirillo M,Stellato D,Laurenzi M,et al.Pulse pressure and isolated systolic hypertension:association with microalbuminuria［J］.Kidney Int,2000,58(3):1211-1218.

［186］Hill gS,Heudes D,Bariety J.Morphometric study of arterioles and glomeruli inthe aging kidney suggests focal loss of autoregulation［J］.Kidney Int,2003,63(3):1027-1036.

［187］Hill gS,Heudes D,Jacquot C,et al.Morphometric evidence for impairment of renal autoregulation in advanced essential hypertension［J］.Kidney Int,2006,69(5):823-831.

［188］Bidani A K,Schwartz M,Lewis E.Renal autoregulation and vulnerability to hypertensive injury in remnant kidney［J］.Am J Physiol,1987,252(6 pt 2):F1003-F1010.

［189］Griffin K A,Kramer H,Bidani A K.Adverse renal consequences of obesity［J］.Am J Physiol Renal Physiol,2008,294(4):F685-F696.

［190］Bidani A K,Mitchell K D,Schwartz M M,et al.Absence of glomerular injury or nephron loss in a normotensive rat remnant kidney model［J］.Kidney Int,1990,38(1):28-38.

［191］Arensbak B,Mikkelsen H B,Gustafsson F,et al.Expression of connexin 37,40,and 43 mRNA and protein in renal preglomerular arterioles［J］.Histochem Cell Bio,2011,115(6):479-487.

［192］Sterze L,Luftfc,Gao Y,et al.Renal disease and the development of hypertension in salt-sensitive Dahl rats［J］.Kidney Int,1988,33(6):1119-1129.

［193］Nath K A.Tubulointerstitial changes as a major determinant in the progression of renal damage［J］.Am J Kidney Dis,1992,20(1):1-17.

［194］Pelayo J C,Westcott J Y.Impaired autoregulation of glomerular capillary hydrostatic pressure in the rat remnant nephron［J］.J Clin Invest,1991,88(1):101-105.

［195］Kim J S,Han B G,Choi S O,et al.Secondary focal segmental glomerulosclerosis:from podocyte injury to glomerulosclerosis［J］.Biomed Res Int,2016(2016):1630365.

［196］Liu Y,Hitomi H,Diah S,et al.Roles of Na(+)/H(+) exchanger type 1 and intracellular pH in angiotensin Ⅱ-induced reactive oxygen species generation and podocyte apoptosis［J］.Pharmacol Sci,2013,122(3):176-183.

［197］Nagata M.Podocyte injury and its consequences［J］.Kidney Int,2016,89(6):1221-1230.

［198］Shankland S J.The podocyte’s response to injury:role in proteinuria and glomerulosclerosis［J］.Kidney Int,2006,69(12):2131-2147.

［199］Loeffler I,Wolf G.Epithelial-to-mesenchymal transition in diabetic nephropathy:fact or fiction?［J］.Cells,2015,4(4):631-652.

［200］Macconi D,Ghilardi M,Bonassi M E,et al.Effect of angiotensin-converting enzyme inhibition on glomerular basement membrane permeability and distribution of zonula occludens-1 in MWF rats［J］.Am Soc Nephrol,2000,11(3):477-489.

［201］Ding G,Reddy K,Kapasi A A,et al.AngiotensinⅡinduces apoptosis in rat glomerular epithelial cells［J］.Am J Physiol Renal Physiol,2002,283(1):F173-F180.

［202］Ronco P,Debiec H.Target antigens and nephritogenic antibodies in membranous nephropathy:of rats and men［J］.Semin Immunopathol,2007,29(4):445-458.

［203］Bai C,Liang S,Wang Y,et al.Knocking down TCF8 inhibits high glucose-and angiotensin Ⅱ-induced epithelial to mesenchymal transition in podocytes［J］.Biosci Trends,2017,11(1):77-84.

［204］Greka A,Mundel P.Balancing calcium signals through TRPC5 and TRPC6 in podocytes［J］.J Am Soc Nephrol,2011,22(11):1969-1980.

［205］Pan M,Maitin V,Parathath S,et al.Presecretory oxidation,aggregation,and autophagic destruction of apoprotein-B:a pathway for late-stage quality control［J］.Proc Natl Acad Sci USA,2008,105(15):5862-5867.

［206］De Rechter S,Decuypere J P,Ivanova E,et al.Autophagy in renal diseases［J］.Pediatr Nephrol,2016,31(5):737-752.

［207］Kretzler M,Koeppen-Hagemann I,Kriz W.Podocyte damage is a critical step in the development of glomerulosclerosis in the uninephrectomised-desoxycorticosterone hypertensive rat［J］.Virchows Arch,1994,425(2):181-193.

［208］Zoja C,Benigni A,Remuzzi G.Cellular responses to protein overload:key event in renal disease progression［J］.Curr Opin Nephrol Hypertens,2004,13(1):31-37.

［209］Peired A.Proteinuria impairs podocyte regeneration by sequestering retinoic acid［J］.J Am Soc Nephrol,2013,24(11):1756-1768.

［210］Sakamoto K.The direction and role of phenotypic transition between podocytes and parietal epithelial cells in focal segmental glomerulosclerosis［J］.Am J Physiol Renal Physiol,2014,306(1):F98-F104.

［211］Wanner N,Hartleben B,Herbach N,et al.Unraveling the role of podocyte turnover in glomerular aging and injury［J］.J Am Soc Nephrol,2014,25(4):707-716.

［212］Pippin J W,Sparks M A,Glenn S T,et al.Cells of renin lineage are progenitors of podocytes and parietal epithelial cells in experimental glomerular disease［J］.Am J Pathol,2013,183(2):542-557.

［213］Sawada N,Itoh H,Ueyama K,et al.Inhibition of rho-associated kinase results in suppression of neointimal formation of balloon-injured arteries［J］.Circulation,2000,101(17):2030-2033.

［214］Miyata K,Shimokawa H,Kandabashi T,et al.Rho-kinase is involved in macrophage-mediated formation of coronary vascular lesions in pigs in vivo［J］.Arterioscler Thromb Vasc Biol,2000,20(11):2351-2358.

［215］Wakino S,Hayashi K,Kanda T,et al.Peroxisome proliferator-activated receptor γ ligands inhibit Rho/Rho kinase pathway by inducing protein tyrosine phosphatase SHP-2［J］.Circ Res,2004,95(5):e45-e55.

［216］Kanda T,Hayashi K,Wakino S,et al.Role of Rho-kinase and p27 in angiotensin Ⅱinduced vascular injury［J］.Hypertension,2005,45(4):724-729.

［217］Tanaka H,Komikado C,Shimada H,et al.The R(-)-enantiomer of efonidipine blocks T-type but not L-type calcium current in guinea pig ventricular myocardium［J］.Journal Pharmacol Sci,2004,96(4):499-501.

［218］Nakamura A,Hayashi K,Ozawa Y,et al.Vessel-and vasoconstrictor-dependent role Rho/Rho-kinase in renal microvascular tone［J］.Vasc Res,2003,40(3):244-251.

［219］Cavarape A,Endlich N,Assaloni R,et al.Rho-kinase inhibition blunts renal vasoconstriction induced by distinct signaling pathways in vivo［J］.Journal Am Soc Nephrol,2003,14(1):37-45.

［220］Carmines P K,Perry M D,Hazelrig J B,et al.Effects of preglomerular and post glomerular vascular resistance alterations of filtration fraction［J］.Kidney Int,1987(20):S229-S232.

［221］Anderson R J,Ray C J,Popoff M R.Evidence for Rho protein regulation of renal tubular epithelial cell function［J］.Kidney Int,2000,58(5):1996-2006.

［222］Thiery J P.Epithelial-mesenchymal transitions in development and pathologies［J］.Curr Opin Cell Biol,2003,15(6):740-746.

［223］Wu Y,Zhou B P.New insights of epithelialmesenchymal transition in cancer metastasis［J］.Acta Biochim Biophys Sin,2008,40(7):643-650.

［224］Liu Y.Epithelial to mesenchymal transition in renal fibrogenesis:Pathologic significance,molecular mechanism,and therapeutic intervention［J］.Journal Am Soc Nephrol,2004,15(1):1-12.

［225］Kalluri R,Neilson E G.Epithelial-mesenchymal transition and its implications for fibrosis［J］.Journal Clin Invest,2003,112(12):1776-1784.

［226］Zavadil J,Bottinger E P.TGF-beta and epithelial-to-mesenchymal transitions［J］.Oncogene,2005,24(37):5764 -5774.

［227］Zeisberg M,Neilson E G.Biomarkers for epithelial-mesenchymal transitions［J］.Journal Clin Invest,2009,119(6):1429 -1437.

［228］Ribatti D.Epithelial-mesenchymal transition in morphogenesis,cancer progression and angiogenesis ［J］.Exp Cell Res,2017,353(1):1-5.

［229］Piera-Velazquez S,Li Z,Jimenez S A.Role of endothelial-mesenchymal transition (EndoMT) in the pathogenesis of fibrotic disorders［J］.Am Journal Pathol,2011,179(3):1074-1080.

［230］Kaschina E,Unger T.Angiotensin AT1/AT2 receptors:regulation,signalling and function［J］.Blood Press,2003,12(2):70-88.

［231］Sterzel R B,Luft F C,Gao Y,et al.Renal disease and the development of hypertension in saltsensitive Dahl rats［J］.Kidney Int,1988,33(6):1119-1129.

［232］Gunaratnam L,Bonventre J V.HIF in kidney disease and development［J］.Journal Am Soc Nephro,2009,20(9):1877-1887.

［233］Haase V H.Oxygen regulates epithelial-to-mesenchymal transition:insights into molecular mechanisms and relevance to disease［J］.Kidney Int,2009,76(5):492-499.

［234］Hochheiser K,Engel D R,Hammerich L,et al.Kidney dendritic cells become pathogenic during crescentic glomerulonephritis with proteinuria［J］.Journal Am Soc Nephrol,2011,22(2):306-316.

［235］Pate M,Damarla V,Chi D S,et al.Endothelial cell biology:role in the inflammatory response［J］.Adv Clin Chem,2010(52):109-130.

［236］Duffield J S.Macrophages and immunologic inflammation of the kidney［J］.Semin Nephrol,2010,30(3):234-254.

［237］Tapmeier T T,Fearn A,Brown K,et al.Pivotal role of CD4+ T cells in renal fibrosis following ureteric obstruction［J］.Kidney Int,2010,78(4):351-362.

［238］Vernon M A,Mylonas K J,Hughes J.Macrophages and renal fibrosis［J］.Semin.Nephro,2010,30(3):302-317.

［239］Gandolfo M T,Jang H R,Bagnasco S M,et al.Foxp3+ regulatory T cells participate in repair of ischemic acute kidney injury［J］.Kidney Int,2009,76(7):717-729.

［240］Cao Q.IL-10/TGF-β-modified macrophages induce regulatory T cells and protect against adriamycin nephrosis［J］.J Am Soc Nephrol,2010,21(6):933-942.

［241］Nishida M,Fujinaka H,Matsusaka T,et al.Absence of angiotensin Ⅱtype 1 receptor in bone marrow-derived cells is detrimental in the evolution of renal fibrosis［J］.Journal Clin Invest,2002,110(12):1859-1868.

［242］Ma L J,Yang H C,Gaspert A,et al.Transforming growth factor β (TGF-β) dependent and independent pathways of induction of tubulointerstitial fibrosis in β6-/-mice［J］.Am Journal Pathol,2003,163(4):1261-1273.

［243］Cao C,Lawrence D A,Li Y,et al.Endocytic receptor LRP together with tPA and PAI-1 coordinates Mac-1-dependent macrophage migration［J］.Embo J,2006,25(9):1860-1870.

［244］Kaissling B,Le Hir M.The renal cortical interstitium:morphological and functional aspects［J］.Histochem Cell Biol,2008,130(2):247-262.

［245］John R,Nelson P J.Dendritic cells in the kidney［J］.Journal Am.Soc.Nephrol,2007,18(10):2628-2635.

［246］Heymann F.Kidney dendritic cell activation is required for progression of renal disease in a mouse model of glomerular injury［J］.Journal Clin Invest,2009,119(5):1286-1297.

［247］Muller D N,Shagdarsuren E,Park J K,et al.Immunosuppressive treatment protects against angiotensin II-induced renal damage［J］.Am J Pathol,2002,161(5):1679-1693.

［248］Bolton C H,Downs L G,Victory J G,et al.Endothelial dysfunction in chronic renal failure:roles of lipoprotein oxidation and pro-inflammatory cytokines［J］.Nephrol Dial Transplant,2001,16(6):1189-1197.

［249］Boo Y C.Shear stress stimulates phosphorylation of protein kinase A substrate proteins including endothelial nitric oxide synthase in endothelial cells［J］.Exp Mol Med,2006,38(4):453.

［250］Venkatachalam M A,Griffin K A,Lan R P,et al.Acute kidney injury:a springboard for progression in chronic kidney disease［J］.Am Journal Physiol Renal Physiol,2010,298(5):F1078-F1094.

［251］Kelly K J,Burford J L,Dominguez J H.Postischemic inflammatory syndrome:a critical mechanism of progression in diabetic nephropathy［J］.Am Journal Physiol Renal Physiol,2009,297(4):F923-F931.

［252］Guo Z J,Niu H X,Hou F F,et al.Advanced oxidation protein products activate vascular endothelial cells via a RAGE-mediated signaling pathway［J］.Antioxid.Redox Signal,2008,10(10):1699-1712.

［253］Duan Y,Gotoh N,Yan Q,et al.Shear-induced reorganization of renal proximal tubule cell actin cytoskeleton and apical junctional complexes［J］.Proc Natl Acad Sci USA,2008,105(32):11418 -11423.

［254］Essig M,Terzi F,Burtin M,et al.Mechanical strains induced by tubular flow affect the phenotype of proximal tubular cells［J］.Am J Physiol Renal Physiol,2001,281(4):F751-F762.

［255］László K,Juszkó J,Bálint P.Renal haemodynamics prior to and after release of 24 hr unilateral ureteral ligation in the dog［J］.Acta Physiol Acad Sci Hung,1978,52(1):71-86.

［256］杨晓萍，黄燕莉，王杰.肾纤维化信号通路的中医药研究进展［J］.世界中医药，2019（5）：22-22.

［257］邹国辉，刘丕.苦参碱调控TGF-β/Smad2 信号通路逆转大鼠胰腺纤维化的作用研究［J］.江西医药，2019，2（4）：33-34.

［258］Hill gS.Hypertensive nephrosclerosis［J］.Curr Opin Nephrol Hypertens,2008,17(3):266-270.

［259］Bascands J L,Schanstra J P.Bradykinin and renal fibrosis:have we ACE’d it?［J］.Journal Am Soc Nephrol,2004,15(9):2504-2506.

［260］Dussaule J C,Guerrot D,Huby A C,et al.The role of cell plasticity in progression and reversal of renal fibrosis［J］.Int J Exp Pathol,2011,92(3):151-157.

［261］Iwano M,Plieth D,Danoff T M,et al.Evidence that fibroblasts derive from epithelium during tissue fifibrosis［J］.Journal Clin Invest,2002,110(3):341-350.

［262］Klahr S,Morrissey J J.The role of vasoactive compounds,growth factors and cytokines in the progression of renal disease［J］.Kidney Int Suppl,2000(75):S7-S14.

［263］Yoshioka K,Takemura T,Tohda M,et al.Glomerular localization of type Ⅲcollagen in human kidney disease［J］.Kidney Int,1989,35(5):1203-1211.

［264］Morel-Maroger Striker L,Killen P D,Chi E,et al.The composition of glomerulosclerosis［J］.Lab Invest,1984,51(2):181-192.

［265］Stokes M B,Hudkins K L,Zaharia V,et al.Up-regulation of extracellular matrix proteoglycans and collagen type I in human crescentic glomerulonephritis［J］.Kidney Int,2001,59(2):532-542.

［266］Smith S W,Schrimpf C,Parekh D J,et al.Kidney pericytes:a novel therapeutic target in interstitial fibrosis［J］.Histol Histopathol,2012,27(12):1503-1514.

［267］Humphreys B D,Lin S L,Kobayashi A,et al.Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis［J］.Am Journal Pathol,2010,176(1):85-97.

［268］Lin S L,Kisseleva T,Brenner D A,et al.Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney［J］.Am Journal Pathol,2008,173(6):1617-1627.

［269］Duffield J S,Lupher M,Thannickal V J,et al.Host responses in tissue repair and fibrosis［J］.Annu Rev Pathol,2013(8):241-276.

［270］Eddy A A.Molecular basis of renal fibrosis［J］.Pediatr Nephrol,2000,15(3-4):290-301.

［271］Liu Y.Renal fibrosis:new insights into the pathogenesis and therapeutics［J］.Kidney Int,2006,69(2):213-7.

［272］Chatziantoniou C,Boffa J J,Tharaux P L,et al.Progression and regression in renal vascular and glomerular fibrosis［J］.Int J Exp Pathol,2004,85(1):1-11.

［273］Bechtel W,McGoohan S,Zeisberg E M,et al.Methylation determines fibroblast activation and fibrogenesis in the kidney［J］.Nat Med,2010,16(5):544-550.

［274］Rock J R,Barkauskas C E,Cronce M J,et al.Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition［J］.Proc Natl Acad Sci USA,2011,108(52):E1475-E1483.

［275］Tanaka H,Komikado C,Shimada H,et al.The R(-)-enantiomer of efonidipine blocks T-type but not L-type calcium current in guinea pig ventricular myocardium［J］.Journal Pharmacol Sci,2004,96(4):499-501.

［276］Nakamura A,Hayashi K,Ozawa Y,et al.Vessel-and vasoconstrictor-dependent role Rho/Rho-kinase in renal microvascular tone［J］.Vasc Res,2003,40(3):244-251.

［277］Zeisberg M,Kalluri R.Fibroblasts emerge via epithelial-mesenchymal transition in chronic kidney fibrosis［J］.Front Biosci,2008(23):6991-6998.

［278］Flier S N,Tanjore T,Kokkotou E G,et al.Identification of epithelial to mesenchymal transition as a novel source of fibroblasts in intestinal fibrosis［J］.Journal Biol Chem,2010,285(26):20202-20212.

［279］Seccia T M,Caroccia B,Gioco F,et al.Endothelin-1 Drives Epithelial-Mesenchymal Transition in Hypertensive Nephroangiosclerosis［J］.Journal Am Heart Assoc,2016,5(7):e003888.

［280］Carvajal G,Rodríguez-Vita J,Rodrigues-Díez R,et al.AngiotensinⅡactivates the Smad pathway during epithelial mesenchymal transdifferentiation［J］.Kidney Int.,2008,74(5):585-595.

［281］Iwano M,Plieth D,Danoff T M,et al.Evidence that fibroblasts derive from epithelium during tissue fibrosis［J］.J Clin Invest,2002,110(3):341-350.

［282］Zeisberg M,Duffield J S.Resolved:EMT produces fibroblasts in the kidney［J］.Journal Am Soc Nephrol,2010,21(8):1247-1253.

［283］Ikushima H,Miyazono K.Biology of transforming growth factor signaling［J］.Curr Pharm Biotechnol.2010,12(12):2099-2107.

［284］Poncelet A C,de Caestecker M P,Schnaper H W.The transforming growth factor-beta/SMAD signaling pathway is present and functional in human mesangial cells［J］.Kidney Int,1999,56(4):1354 -1365.

［285］Soond S M,Chantry A.Selective targeting of activating and inhibitory Smads by distinct WWP2 ubiquitin ligase isoforms differentially modulates TGF signalling and EMT［J］.Oncogene,2011,30(21):2451-2462.

［286］Tang L Y,Yamashita M,Coussens N P,et al.Ablation of Smurf 2 reveals an inhibition in TGF signalling through multiple mono-ubiquitination of Smad3［J］.EMBO J,2011,30(23):4777-4789.

［287］Zeisberg M,Yang C,Martino M,et al.Fibroblasts derive from hepatocytes in liver fibrosis viaepithelial to mesenchymal transition［J］.Journal Biol Chem,2007,282(32):23337-23347.

［288］He W,Tan R,Dai C,et al.Plasminogen activator inhibitor-1 is a transcriptional target of the canonical pathway of Wnt/β-catenin signaling［J］.Journal Biol.Chem,2010,285(32):24665-24675.

［289］Berge D T,Koole W,Fuerer C,et al.Wnt signaling mediates selforganization and axis formation in embryoid bodies［J］.Cell Stem Cell,2008,3(5):508-518.

［290］Li Y,Yang J,Dai C,et al.Role for integrin-linked kinase in mediating tubular epithelial to mesenchymal transition and renal interstitial fibrogenesis［J］.Journal Clin.Invest,2003,112(4):503-516.

［291］Liu X C,Liu B C,Zhang X L,et al.Role of ERK1/2 and PI3-K in the regulation of CTGF-induced ILK expression in HK-2 cells［J］.Clin.Chim.Acta,2007,382(1-2):89-94.

［292］Strutz F,Zeisberg M.Renal fibroblasts and myofibroblasts in chronic kidney disease［J］.Journal Am Soc Nephrol,2006,17(11):2992-2998.

［293］Weinbaum S,Duan Y,Satlin L M,et al.Mechanotransduction in the renal tubule［J］.Am Journal Physiol Renal Physiol,2010,299(6):F1220-F1236.

［294］Chatziantoniou C,Boffa J J,Tharaux P L,et al.Progression and regression in renal vascular and glomerular fibrosis［J］.Int Journal Exp Pathol,2004,85(1):1-11.

［295］Grande M T,López-Novoa J M.Fibroblast activation and myofibroblast generation in obstructive nephropathy［J］.Nat Rev Nephrol,2009,5(6):319-328.

［296］Schrimpf C,Duffield J S.Mechanisms of fibrosis:the role of the pericyte［J］.Curr Opin Nephrol Hypertens,2011,20(3):297-305.

［297］Boor P,Ostendorf T,Floege J.Renal fibrosis:novel insights into mechanisms and therapeutic targets［J］.Nat.Rev.Nephrol,2010,6(11):643-656.

［298］Wynn T A.Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases［J］.Journal Clin Invest,2007,117(3):524-529.

［299］Hinz B,Phan S H,Thannickal V J,et al.The myofibroblast:one function,multiple origins［J］.Am J Pathol,2007,170(6):1807-1816.

［300］Kaissling B,Le Hir M.The renal cortical interstitium:morphological and functional aspects［J］.Histochem Cell Biol,2008,130(2):247-262.

［301］Lin S L,Kisseleva T,Brenner D A,et al.Pericytes and perivascular fibroblasts are the primary source of collagen producing cells in obstructive fibrosis of the kidney［J］.Am Journal Pathol,2008,173(6):1617-1627.

［302］Zou J,Yaoita E,Watanabe Y,et al.Upregulation of nestin,vimentin,and desmin in rat podocytes in response to injury［J］.Virchows Arch,2006,448(4):485-492.

［303］Keeley E C,Mehrad B,Strieter R M.Fibrocytes:bringing new insights into mechanisms of inflammation and fibrosis［J］.Int Journal Biochem Cell Biol,2010,42(4):535-542.

［304］Kim J K,Kim J H,Lee S C,et al.Clinical features and outcomes of IgA nephropathy with nephrotic syndrome［J］.Clin Journal Am Soc Nephrol,2012,7(3):427-436.

［305］Kitamura M,Sütö T S.TGF-beta and glomerulonephritis:anti-inflammatory versus prosclerotic actions［J］.Nephrol Dial Transplant,1997,12(4):669 -679.

［306］Meran S.Fibroblasts and myofibroblasts in renal fibrosis［J］.Int Journal Exp Pathol,2011,92(3):158-167.

［307］Eddy A A.Progression in chronic kidney disease［J］.Adv Chronic Kidney Dis,2005,12(4):353-365.

［308］Bradshaw A D.The role of SPARC in extracellular matrix assembly［J］.Cell Commun Signal,2009,3(3-4):239-246.

［309］Weaver M S,Workman G,Sage E H.The copper binding domain of SPARC mediates cell survival in vitro via interaction with integrin β1 and activation of integrin-linked kinase［J］.Journal Biol Chem,2008,283(33):22826-22837.

［310］Shweke N.Tissue transglutaminase contributes to interstitial renal fibrosis by favoring accumulation of fibrillar collagen through TGF-β activation and cell infiltration［J］.Am Journal Pathol,2008,173(3):631-642.

［311］Wang B,Koh P,Winbanks C,et al.miR-200a prevents renal fibrogenesis through repression of TGF-β2 expression［J］.Diabetes,2011,60(1):280-287.

［312］Kato M.A microRNA circuit mediates transforming growth factor-β1 autoregulation in renal glomerular mesangial cells［J］.Kidney Int,2011,80(4):358-368.

［313］Inui M,Martello G,Piccolo S.MicroRNA control of signal transduction［J］.Nat Rev Mol Cell Biol,2010,11(4):252-263.

［314］Eyden B.Fibronexus junctions associated with in vivo human endothelium［J］.Ultrastruct Patho,2009,33(1):28-32.

［315］Margadant C,Sonnenberg A.Integrin-TGF-β crosstalk in fibrosis,cancer and wound healing［J］.EMBO Rep,2010,11(2):97-105.

［316］Legate K R,Fässler R.Mechanisms that regulate adaptor binding to β-integrin cytoplasmic tails［J］.Cell Sci,2009,12(pt 2):187-198.

［317］Wang X.Mice lacking the matrix metalloproteinase-9 gene reduce renal interstitial fibrosis in obstructive nephropathy［J］.Am.Journal Physiol.Renal Physiol,2010,299(5):F973-F982.

［318］Fogo A B.Progression and potential regression of glomerulosclerosis［J］.Kidney Int,2010,59(2):804-819.

［319］Liu Y.Hepatocyte growth factor in kidney fibrosis:therapeutic potential and mechanisms of action［J］.Am Journal Physiol Renal Physio,2004,287(1):7-16.

［320］Nahas A M,Muchaneta-Kubara EC,Essawy M,et al.Renal fibrosis:insights into pathogenesis and treatment［J］.Int Journal Biochem Cell Biol,1997,29(1):55-62.

［321］Wei Q,Mi Q S,Dong Z.The regulation and function of microRNAs in kidney diseases［J］.IUBMB Life,2013,65(7):602-614.

［322］D’Agati V,Schmidt A M.RAGE and the pathogenesis of chronic kidney disease［J］.Nature Review Nephrol,2010,6(6):352-360.

［323］Kaschina E,Unger T.Angiotensin AT1/AT2 receptors:regulation,signalling and function［M］.Blood Press,2003.

［324］Turner A J,Hiscox J A,Hooper N M.ACE2:from vasopeptidase to SARS virus receptor［J］.Trends Pharmacol Sci,2004,25(6):291-294.

［325］Ferrario C M,ChAppell M C.Novel angiotensin peptides［J］.Cell Mol Life Sci,2004,61(21):2720-2727.

［326］Nguyen G.The (pro)renin receptor:pathophysiological roles in cardiovascular and renal pathology［J］.Curr Opin Nephrol Hypertens,2007,16(2):129-133.

［327］Ruster C,Wolf G.Angiotensin Ⅱas a morphogenic cytokine stimulating renal fibrogenesis ［J］.Am Soc Nephrol,2011,22(7):1189-1199.

［328］Zhou Y,Yu J,Liu J,et al.Induction of cytochrome P450 4A14 contributes to angiotensin Ⅱ-induced renal fibrosis in mice［J］.Biochim Biophys Acta,2018,1864(3):860-870.

［329］Anders H J,Schaefer L.Beyond tissue injury-damage-associated molecular patterns,toll like receptors,and inflammasomes also drive regeneration and fibrosis［J］.Journal of the American Society of Nephrology:JASN,2014,25(7):1387-1400.

［330］Omata M,Taniguchi H,Koya D,et al.N-acetyl-seryl-aspartyllysyl-proline ameliorates the progression of renal dysfunction and fibrosis in WKY rats with established anti-glomerular basement membrane nephritis［J］.Journal Am Soc Nephrol,2006,17(3):674-685.

［331］Shibuya K,Kanasaki K,Isono M,et al.N-acetyl-seryl-aspartyl-lysyl-proline prevents renal insufficiency and mesangial matrix expansion in diabetic db/db mice［J］.Diabetes,2005,54(3):838-845.

［332］Rock J R,et al.Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition［J］.Proc Natl Acad Sci U S A,2011,108(52):E1475-E1483.

［333］Hamano Y,Grunkemeyer J A,Sudhakar A,et al.Determinants of vascular permeability in the kidney glomerulus［J］.J Biol Chem,200,277(34):31154-31162.

［334］Vaughan E D,Sorenson E J,Gillenwater J Y.The renal hemodynamicresponse to chronic unilateral complete ureteral occlusion［J］.Invest Urol,1970,8(1):78 -90.(https://www.daowen.com)

［335］Liu Y.Hepatocyte growth factor in kidney fibrosis:therapeutic potential and mechanisms of action［J］.Am Journal Physiol Renal Physiol,2004,287(1):F7-F16.

［336］Schlessinger S D,Tankersley M R,Curtis J J.Clinical documentation of end-stage renal disease due to hypertension［J］.Am J Kidney Dis,1994,23(5):655-660.

［337］Fogo A.Breyer J A,Smith M C,et al.Accuracy of the diagnosis of hypertensive nephrosclerosis in African American Study of Kidney Disease (AASK) Trial.AASK Pilot Study Investigators［J］.Kidney Int,1997,51(1):244-252.

［338］王海燕.肾脏病学［M］.3 版.北京：人民卫生出版社，2008.

［339］Zarif L,Covic A,Iyengar S,et al.Inaccuracy of clinical phenotyping parameters for hypertensive nephrosclerosis［J］.Nephrol Dial Transplant,2000,15(11):1801-1807.

［340］黎磊石，刘志红.中国肾脏病学［M］.北京：人民军医出版社，2008.

［341］Kincaid-Smith P,McMicheal J,Murphy E A.The clinical course and pathology of hypertension with papilloedema (malignant hypertension)［J］.Quarterly Journal of Medicine,1958,27(105):117-153.

［342］Paronetto F.Immunocytochemical observations on the vascular necrosis and renal glomerular lesions of malignant nephrosclerosis［J］.Am Journal Pathol,1965,46(6):901-915.

［343］郑法雷，章友康，陈香美，等.肾脏病临床与进展［M］.北京：人民军医出版社，2005：190-198.

［344］周福德，刘玉春，邹万忠，等.以肾脏受累为表现的恶性高血压的临床病理分析［J］.中华内科杂志，2001，40（3）：165-168.

［345］中华医学会肾脏病学分会.临床诊疗指南肾脏病学分册［M］.北京：人民卫生出版社，2009.

［346］Sinclair R A,Antonovych T T,Mostofi F K.Renal proliferative arteriopathies and associated glomerular changes.A light and electron microscopic study［J］.Hum Pathol,1976,7(5):565-588.

［347］Nolan C R.Malignant Hypertension and Other Hypertensive Crises//Schrier RW.Diseases of the Kidney and Urinary Tract［M］.7th ed.Philadelphia:Lippincott Williams and Wilkins,2001:1513-1592.

［348］王吉耀.八年制内科学［M］.2 版.北京：人民卫生出版社，2010.

［349］ Lip gY,Beevers M,Beevers G.The failure of malignant hypertension to decline:a survey of 24 years experience in a multiracial population in England［J］.J Hypertens,1994,12(11):1297-1305.

［350］黄淑文，刘立生.20例恶性高血压诊断与治疗的临床分析［J］.中国循环杂志，1990，5（2）：119-121.

［351］Paul L K，Mark E R，庄守纲，等.慢性肾脏病［M］.北京：人民卫生出版社，2018.

［352］Monhart V.KDIGO Clinical practice guideline for the management of blood pressure in chronic kidney disease［J］.Kidney Int Suppl,2012,2(4):337-414.

［353］王海燕.肾脏病学［M］.北京：人民卫生出版社，2016.

［354］程虹，谌贻璞.血管紧张素转换酶抑制剂在肾脏疾病治疗中的合理应用［J］.中国医药导刊，2002，2（1）：279-280.

［355］黎磊石，刘志红.中国肾脏病学［M］.北京：人民军医出版，2008.

［356］中华医学会.临床诊疗指南肾脏病学分册［M］.北京：人民卫生出版社，2011.

［357］中国中西医结合学会肾脏疾病专业委员会.慢性肾衰竭中西医结合诊疗指南［J］.中国中西医结合杂志，2015，25（9）：1029-1033.

［358］de Brito-Ashurst I,Varagunam M,Rafter M J.Bicarbonate supplementation slows progression of CKD and improves nutritional status［J］.Journal Am Soc Nephrol,2009,20(9):2075-2084.

［359］Mahajan A,Simoni J,Sheater S J,et al.Daily oral sodium bicarbonate preservers glomerular filtration rate by slowing its decline in early hypertensive nephropathy［J］.Kidney Int,2010,78(3):303-309.

［360］Jiv M M,Parfrey P S,AI E.KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease［J］.Kidney Int Suppl,2012,2(4):1-335.

［361］National Kidney Foundation.KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease:2007 UPDATE OF HEMOGLOBIN TARGET［J］.Am Journal Kidney Dis,2007,50(3):476-509.

［362］Kidney F N,Kidney D.KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease［J］.Kidney Int Suppl,2013,3(1):1-150.

［363］National Kidney Foundation.KDOQI clinical practice guidelines for chronic kidney disease:evaluation,classification,and stratification［J］.Am Journal Kidney Dis,2002,39(2 suppl 1):1-266.

［364］活性维生素D的合理应用专家协作组.活性维生素D在慢性肾脏病继发性甲旁亢中合理应用的专家共识［J］.中华肾脏病杂志，2005，21（11）：698-699.

［365］王莉，李贵森，刘志红.慢性肾脏病矿物质和骨异常诊治指导［J］.肾脏病与透析肾移植杂志，2013，22（6）：554-559.

［366］国家卫生健康委员会疾病预防控制.中国高血压健康管理规范（2019）［J］.中华心血管病杂志，2020，48（1）：10-46.

［367］中国医师协会康复医师分会肾康复专业委员会.我国成人慢性肾脏病患者运动康复的专家共识［J］.中华肾脏病杂志，2019，35（7）：537-541.

［368］Kitiyakara C,Guzman N J.Malignant hypertension and hypertensive emergencies［J］.Journal of the American Society of Nephrology,1998,9(1):133-142.

［369］Neutel J M,Smith D H,Wallin D.Hypertensive emergencies［J］.Lancet,2000,356(1):411-417.

［370］Udani S,Lazich I,Bakris gL.Epidemiology of hypertensive kidney disease［J］.Nature Reviews Nephrology,2011,7(1):11-21.

［371］Freedman B I,Cohen A H.Hypertension-attributed nephropathy:what’s in a name?［J］.Nature Reviews Nephrology,2016,12(1):27-36.

［372］Leong K T,Walton A,Krum H.Renal sympathetic denervation for the treatment of refractory hypertension［J］.Annual Review of Medicine,2014(65):349-365.

［373］Walker W G.Hypertension-related renal injury:a major contributor to end-stage renal disease［J］.American Journal of Kidney Disease,1993,22(1):164-173.

［374］马全中，郭志勇.高血压肾病的研究现状［J］.中国医药导报，2012，9（33）：32-33.

［375］余翠平.高血压肾损害早期检测指标的研究进展［J］.当代医学，2012，18（25）：26-27.

［376］Acosta A A,McNiece K L.Ambulatory blood pressure monitoring:a versatile tool for evaluating and managing hypertension in children［J］.Pediatric Nephrology,2008,23(9):1399-1408.

［377］刘伏友，孙林.临床肾脏病学［M］.北京：人民卫生出版社，2019.

［378］George J A,Gounden V.Novel glomerular filtration markers［J］.Adv Clin Chem,2019(88):91-119.

［379］Favre G,Schiavo L,Lemoine S,et al.Longitudinal assessment of renal function in native kidney after bariatric surgery［J］.Surg Obes Relat Dis,2018,14(9):1411-1418.

［380］宋文静，李海涛.高血压早期肾损害的检测指标［J］.中国煤炭工业医学杂志，2008（6）：944-946.

［381］Wang Y,Chen C,Yan Y,et al.Association of uric acid in serum and urine with subclinical renal damage:Hanzhong Adolescent Hypertension Study［J］.Plos One,2019,14(11):e224680.

［382］Borghi C,Rosei E A,Bardin T,et al.Serum uric acid and the risk of cardiovascular and renal disease［J］.Journal Hypertens,2015,33(9):1729-1741,1741.

［383］Inker L A,Schmid C H,Tighiouart H,et al.Estimating glomerular filtration rate from serum creatinine and cystatin C［J］.N Engl Journal Med,2012,367(1):20-29.

［384］赵子秀.血清胱蛋白酶抑制剂C测定的临床意义［J］.国外医学.泌尿系统分册，2002（2）：103-104.

［385］Wali U,Hussain M M,Wali N,et al.Comparison of serum levels of Cystatin-C and traditional renal biomarkers for the early detection of pre-hypertensive nephropathy［J］.Journal Pak Med Assoc,2019,69(3):313-319.

［386］Salgado J V,Franca A K,Cabral N A,et al.Cystatin C,kidney function,and cardiovascular risk factors in primary hypertension［J］.Rev Assoc Med Bras (1992),2013,59(1):21-27.

［387］杨晓梅，高建，陈丽，等.视黄醇结合蛋白临床的研究进展［J］.中国民族民间医药，2011，20（01）：30-32.

［388］Norden A G,Lapsley M,Unwin R J.Urine retinol-binding protein 4:a functional biomarker of the proximal renal tubule［J］.Adv Clin Chem,2014(63):85-122.

［389］Li A,Yi B,Liu Y,et al.Urinary NGAL and RBP Are Biomarkers of Normoalbuminuric Renal Insufficiency in Type 2 Diabetes Mellitus［J］.Journal Immunol Res,2019,2019:5063089.

［390］Domingos M A,Moreira S R,Gomez L,et al.Urinary Retinol-Binding Protein:Relationship to Renal Function and Cardiovascular Risk Factors in Chronic Kidney Disease［J］.PLoS One,2016,11(9):e162782.

［391］Xu X,Fang Y,Ji J,et al.Clinical value of urinary kidney biomarkers for estimation of renal impairment in elderly Chinese with essential hypertension［J］.Journal Clin Lab Anal,2008,22(1):86-90.

［392］Blumczynski A,Soltysiak J,Lipkowska K,et al.Hypertensive nephropathy in children-do we diagnose early enough?［J］.Blood Press,2012,21(4):233-239.

［393］成娟歌，王森.N-乙酰-β-D-氨基葡萄糖苷酶的研究现状［J］.中外食品工业（下半月），2014（7）：68-70.

［394］Zhou L T,Lv L L,Pan M M,et al.Are Urinary Tubular Injury Markers Useful in Chronic Kidney Disease? A Systematic Review and Meta Analysis［J］.Plos One,2016,11(12):e167334.

［395］Xu X,Fang Y,Ji J,et al.Clinical value of urinary kidney biomarkers for estimation of renal impairment in elderly Chinese with essential hypertension［J］.Journal Clin Lab Anal,2008,22(1):86-90.

［396］Tylicki L,Manitius J,Lysiak-Szydlowska W,et al.Tubular injury:the first symptom of hypertensive kidney involvement?［J］.Med Sci Monit,2003,9(4):R135-R141.

［397］唐华，邹平，李著华.肾损伤分子-1研究进展［J］.国际检验医学杂志，2006（8）：719-720.

［398］Schrezenmeier E V,Barasch J,Budde K,et al.Biomarkers in acute kidney injury-pathophysiological basis and clinical performance［J］.Acta Physiol (Oxf),2017,219(3):554-572.

［399］Fiseha T,Tamir Z.Urinary Markers of Tubular Injury in Early Diabetic Nephropathy［J］.Int Journal Nephrol,2016,2016:4647685.

［400］Kadioglu T,Uzunlulu M,Yigit K S,et al.Urinary kidney injury molecule-1 levels as a marker of early kidney injury in hypertensive patients［J］.Minerva Urol Nefrol,2016,68(5):456-461.

［401］Seibert F S,Sitz M,Passfall J,et al.Prognostic Value of Urinary Calprotectin,NGAL and KIM-1 in Chronic Kidney Disease［J］.Kidney Blood Press Res,2018,43(4):1255-1262.

［402］须静，胡晓波.中性粒细胞明胶酶相关脂质运载蛋白的研究进展［J］.检验医学，2012，27（10）：871-876.

［403］Blumczynski A,Soltysiak J,Lipkowska K,et al.Hypertensive nephropathy in children-do we diagnose early enough?［J］.Blood Press,2012,21(4):233-239.

［404］Gharishvandi F,Kazerouni F,Ghanei E,et al.Comparative assessment of neutrophil gelatinaseassociated lipocalin (NGAL) and cystatin C as early biomarkers for early detection of renal failure in patients with hypertension［J］.Iran Biomed Journal,2015,19(2):76-81.

［405］Blazquez-Medela A M,Garcia-Sanchez O,Blanco-Gozalo V,et al.Hypertension and hyperglycemia synergize to cause incipient renal tubular alterations resulting in increased NGAL urinary excretion in rats［J］.Plos One,2014,9(8):e105988.

［406］Reboldi G,Gentile G,Angeli F,et al.Microalbuminuria and hypertension［J］.Minerva Med,2005,96(4):261-275.

［407］Biro I,Drahota A,Halasz T.Experiences in medicamentous dysphagia prophylaxis in geriatrics (author’s transl)［J］.Z Alternsforsch,1976,31(1):27-33.

［408］Seeman T,Pohl M,Palyzova D,et al.Microalbuminuria in children with primary and white-coat hypertension［J］.Pediatr Nephrol,2012,27(3):461-467.

［409］Pontremoli R,Leoncini G,Ravera M,et al.Microalbuminuria,cardiovascular,and renal risk in primary hypertension［J］.J Am Soc Nephrol,2002,13 Suppl 3:S169-S172.

［410］Shin J R,Kim S M,Yoo J S,et al.Urinary excretion of beta2-microglobulin as a prognostic marker in immunoglobulin A nephropathy［J］.Korean J Intern Med,2014 ,29(3):334-340.

［411］Cao J,Hou R,Lu J,et al.The predictive value of beta2-MG and TGF-beta for elderly hypertensive nephropathy［J］.Exp Ther Med,2019,17(4):3065-3070.

［412］Zhang L,Sun J,Zhang M,et al.The significance of combined detection of CysC,urinary mAlb and beta2-MG in diagnosis of the early renal injury in pregnancy-induced hypertension syndrome［J］.Saudi J Biol Sci,2019,26(8):1982-1985.

［413］Ahsan A,Manna K,Yadav gS,et al.Protein creatinine index:A possible predictor of nephropathy in hypertensives,in Northern India［J］.Clin Chim Acta,2016(460):18-22.

［414］ 王继伟.尿微量白蛋白/肌酐比值在高血压早期肾损害诊断中的价值［J］.实用中西医结合临床，2010，10（06）：73-74.

［415］杨丹，李丹丹，刘姗姗，等.双酚A对机体的影响及其作用机制［J］.现代预防医学，2008（17）：3280-3282.

［416］Hu J,Wang Y,Xiang X,et al.Serum bisphenol A as a predictor of chronic kidney disease progression in primary hypertension:a 6-year prospective study［J］.Journal Hypertens,2016,34(2):332-337.

［417］Kovarikova S,Marsalek P,Habanova M,et al.Serum concentration of bisphenol A in elderly cats and its association with clinicopathological findings［J］.Journal Feline Med Surg,2020:1098612X-20932260X.

［418］赵世杰，王文荣，安惠霞.骨膜蛋白在各系统疾病中的研究进展［J］.临床与病理杂志，2019，39（08）：1815-1819.

［419］Guerrot D,Dussaule J C,Mael-Ainin M,et al.Identification of periostin as a critical marker of progression/reversal of hypertensive nephropathy［J］.Plos One,2012,7(3):e31974.

［420］Liu Z,Wang Y,Shu S,et al.Non-coding RNAs in kidney injury and repair［J］.Am J Physiol Cell Physiol,2019,317(2):C177-C188.

［421］Guo C,Dong G,Liang X,et al.Epigenetic regulation in AKI and kidney repair:mechanisms and therapeutic implications［J］.Nature Review Nephrol,2019,15(4):220-239.

［422］Huang Y Q,Huang C,Li J,et al.The association of miR-29a with proteinuria in essential hypertension［J］.Journal Hum Hypertens,2018,32(11):775-780.

［423］杨红霞，朱敏怡.彩色多谱勒超声对高血压肾损害的研究［J］.实用医学杂志，2005，21（1）：59.

［424］向莉.肾显像早期诊断原发性高血压肾损害的临床价值［J］.河北医学，2004（3）：207-209.

［425］Volhard F,Fahr T.Die brightsche nierenkrankheir,Klinik,Pathologie and Atlas［M］.Berlin; Verlag von Julius Springer,1914.

［426］Gudbrandsson T,Hansson L,Herlitz H,et al.Malignant hypertension improving prognosis in a rare disease［J］.Acta Med Scand,1979,206(6):495-499.

［427］Lip gY,Beevers M,Beevers G.The failure of malignant hypertension to decline:a survey of 24 years’ experience in a multiracial population in England［J］.Journal Hypertens,1994,12(11):1297-1305.

［428］Milne F J,James S H,Veriava Y.Malignant Hypertension and its renal complications in black South Africans［J］.S Afr Med J,1989,76(4);164-167.

［429］周福德，刘玉春，邹万忠，等.以肾脏受累为表现的恶性高血压的临床病理分析［J］.中华内科杂志，2001，40（3）：165-168.

［430］Scarpelli P T,Livi R,Caselli gM,et al.Accelerated (malignant) hypertension:a study of 121 cases between 1974 and 1996［J］.Journal Nephrol,1997,10(4):207-215.

［431］Yu S H,Whitworth J A,Kincaid-Smith P S.Malignant hypertension:aetiology and outcome in 83 patients［J］.Clin Exp Hypertens A,1986,8(7):1211-1230.

［432］Pickering G.Reversibility of malignant hypertension［J］.Follow-up of three cases.Lancet,1971,1(7696):413-418.

［433］Heptinstall R H.Renal biopsies in hypertension［J］.Br Heart Journal,1954(2),16:133-141.

［434］Goldblatt H.Studies on experimental hypertension.The production of the malignant phase of hypertension［J］.Journal Exp Med,1938(5),67:809-826.

［435］Whitworth C E,Fleming S,Kotelevtsev Y.A genetic model of malignant hypertension in rats［J］.Kidney Int,1995,47(2):529-535.

［436］Nolan C R.Malignant Hypertension and other hypertension Crises.Diseases of the kidney and Urinary Tract.7th ed［M］.Philadelphin:Lippincott Williams and Wilkins,2001.

［437］McAllister R G,Van Way CW,Dayani K.Malignant hypertension:effect of therapy on renin and aldosterone［J］.Cire Res,1971,28(5):160-174.

［438］Hosler gA,Cusumano A M,Hutchins gM.Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities:a review of 56 autopsy cases［J］.Arch Pathol Lab Med,2003,127(7):834-839.

［439］Kohno M,Yokokawa K,Yasunari K.Renoprotective effects of a combined endothelin type A/type B receptor antagonist in experimental malignant hypertension［J］.Metabolism,1997,46(9):1032-1038.

［440］Petitti D B,Klatsky A L.Malignant hypertension in women aged 15 to 44 and its relation to cigarette smoking and oral contraceptives［J］.Am Journal Cardiol,1983,52(3):297-298.

［441］Kazda S,Garthoff B,Luckhaus G.Calcium and malignant hypertension in animal experiment:effects of experimental manipulation of calcium influx［J］.Am Journal Nephrol,1986(6):145-150.

［442］Tobian L,MacNeil D,Johnson M A.Potasium protection against lesions of the renal tubules,arteries,and glomeruli and nephron loss in salt-loaded hypertensive Dahl S rats［J］.Hypertension,1984,6(2 pt 2):170-176.

［443］Tobian L,Lange J,Ulm K.Potassium reduces cerebral hemorrahage and death rate in hypertensive rats,even when blood pressure is not lowered［J］.Hypertension,1985,7(3 Pt 2):110-114.

［444］Ribeiro A B,Schwarzwalder S R,Saragoca M A.Malignant hypertension:A sundrome accompanied by plasmatic diminution of low and high molecular weight kininogens［J］.Hypertension,1983,5(6 Pt 3):V158-162.

［445］Noris M,Remuzzi G.Atypical hemolytic-uremic syndrome［J］.N Engl Journal Med,2009,361(17):1676-1687.

［446］Huang J,Motto D G,Bundle D R,et al.Shiga toxin B subunits induceVWF secretion by human endothelial cells and thrombotic microangiopathy inADAMTS13-deficient mice［J］.Blood,2010,116(18):3653-3659.

［447］Tsai H M.Does anticomplement therapy have a role in the managementof malignant hypertension?［J］.Journal Clin Hypertens,.2016,18(4):359-360.

［448］Levy gG,Nichols W C,Lian E C,et al.Mutations in a member of the ADAMTS gene family cause thrombotic thrombocy-topenic purpura［J］.Nature,2001,413(6855):488-494.

［449］Kremer Hovinga J A,Vesely S K,Terrell D R,et al.Survival andrelapse in patients with thrombotic thrombocytopenic purpura［J］.Blood,2010,115(8):1500-1511.

［450］Wang Z,Chen Z,Zhang L,et al.Status of Hypertension in China:Results From the China Hypertension Survey,2012-2015［J］.Circulation,2018,137(22):2344-2356.

［451］《中国高血压防治指南》修订委员会.中国高血压防治指南2018年修订版［J］.心脑血管防治，2019，19（1）：1.

［452］Hocher B,Adamski J.Metabolomics for clinical use and research in chronic kidney disease［J］.Nature reviews Nephrology,2017,13(5):269-284.

［453］Øvrehus M A,Bruheim P,Ju W,et al.Gene Expression Studies and Targeted Metabolomics Reveal Disturbed Serine,Methionine,and Tyrosine Metabolism in Early Hypertensive Nephrosclerosis［J］.Kidney international reports,2019,4(2):321-333.

［454］Rinschen M M,Palygin O,Guijas C,et al.Metabolic rewiring of the hypertensive kidney［J］.Science signaling,2019,12(611)

［455］Funk C D.Prostaglandins and leukotrienes:advances in eicosanoid biology［J］.Science (New York,NY),2001,294(5548):1871-1875.

［456］Fang Q,Chen gZ,Wang Y,et al.Role of cytochrome P450 epoxygenase-dependent arachidonic acid metabolites in kidney physiology and diseases［J］.Sheng li xue bao:［Acta physiologica Sinica］,2018,70(6):591-599.

［457］Zhao X,Yamamoto T,Newman J W,et al.Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage［J］.Journal of the American Society of Nephrology:JASN,2004,15(5):1244-1253.

［458］Muller D N,Theuer J,Shagdarsuren E,et al.A peroxisome proliferator-activated receptor-alpha activator induces renal CYP2C23 activity and protects from angiotensin Ⅱ-induced renal injury［J］.The American journal of pathology,2004,164(2):521-532.

［459］Kroetz D L,Huse L M,Thuresson A,et al.Developmentally regulated expression of the CYP4A genes in the spontaneously hypertensive rat kidney［J］.Molecular pharmacology,1997,52(3):362-372.

［460］Fan F,Ge Y,Lv W,et al.Molecular mechanisms and cell signaling of 20-hydroxyeicosatetraenoic acid in vascular pathophysiology［J］.Frontiers in bioscience ( Landmark edition ),2016(21):1427-1463.

［461］Fan F,Muroya Y,Roman R J.Cytochrome P450 eicosanoids in hypertension and renal disease［J］.Current opinion in nephrology and hypertension,2015,24(1):37-46.

［462］Zhang C,Booz gW,Yu Q,et al.Conflicting roles of 20-HETE in hypertension and renal end organ damage［J］.European journal of pharmacology,2018(833):190-200.

［463］Mattace Raso G,Simeoli R,Russo R,et al.N-Palmitoylethanolamide protects the kidney from hypertensive injury in spontaneously hypertensive rats via inhibition of oxidative stress［J］.Pharmacological research,2013(76):67-76.

［464］Chen Z,Wu H,Wang G,et al.Identification of potential candidate genes for hypertensive nephropathy based on gene expression profile［J］.BMC nephrology,2016,17(1):149.

［465］Breyer M D,Jacobson H R,Breyer R M.Functional and molecular aspects of renal prostaglandin receptors［J］.Journal of the American Society of Nephrology:JASN,1996,7(1):8-17.

［466］Kawaguchi H,Saito H,Yasuda H.Renal prostaglandins and phospholipase A2 in spontaneously hypertensive rats［J］.Journal of hypertension,1987,5(3):299-304.

［467］Arrazola A,Diez J.Enhanced renal PGE2 in hypertensives with increased red cell Na(+)-Li+ countertransport［J］.The American journal of physiology,1991,261(1 Pt 2):H134-139.

［468］Suganami T,Mori K,Tanaka I,et al.Role of prostaglandin E receptor EP1 subtype in the development of renal injury in genetically hypertensive rats［J］.Hypertension ( Dallas,Tex:1979 ),2003,42(6):1183-1190.

［469］Chen Y Y,Chen D Q,Chen L,et al.Microbiome-metabolome reveals the contribution of gutkidney axis on kidney disease［J］.Journal of translational medicine,2019,17(1):5.

［470］Yang T,Richards E M,Pepine C J,et al.The gut microbiota and the brain-gut-kidney axis in hypertension and chronic kidney disease［J］.Nature reviews Nephrology,2018,14(7):442-456.

［471］Vaziri N D,Wong J,Pahl M,et al.Chronic kidney disease alters intestinal microbial flora［J］.Kidney international,2013,83(2):308-315.

［472］Ramezani A,Raj D S.The gut microbiome,kidney disease,and targeted interventions［J］.Journal of the American Society of Nephrology:JASN,2014,25(4):657-670.

［473］Andrade-Oliveira V,Amano M T,Correa-Costa M,et al.Gut Bacteria Products Prevent AKI Induced by Ischemia-Reperfusion［J］.Journal of the American Society of Nephrology:JASN,2015,26(8):1877-1888.

［474］Bellahcene M,O’Dowd J F,Wargent E T,et al.Male mice that lack the G-protein-coupled receptor GPR41 have low energy expenditure and increased body fat content［J］.The British journal of nutrition,2013,109(10):1755-1764.

［475］Bindels L B,Porporato P,Dewulf E M,et al.Gut microbiota-derived propionate reduces cancer cell proliferation in the liver［J］.British journal of cancer,2012,107(8):1337-1344.

［476］Høverstad T,Midtvedt T.Short-chain fatty acids in germfree mice and rats［J］.The Journal of nutrition,1986,116(9):1772-1776.

［477］Perry R J,Peng L,Barry N A,et al.Acetate mediates a microbiome-brain-β-cell axis to promote metabolic syndrome［J］.Nature,2016,534(7606):213-217.

［478］Coady M J,Chang M H,Charron F M,et al.The human tumour suppressor gene SLC5A8 expresses a Na+-monocarboxylate cotransporter［J］.The Journal of physiology,2004,557(Pt 3):719-731.

［479］Mortensen F V,Nielsen H,Mulvany M J,et al.Short chain fatty acids dilate isolated human colonic resistance arteries［J］.Gut,1991,31(12):1391-1394.

［480］Pirkle J L,Freedman B I.Hypertension and chronic kidney disease:controversies in pathogenesis and treatment［J］.Minerva Urol Nefrol 2013,65(1):37-50.

［481］Wong J,Piceno Y M,DeSantis T Z,et al.Expansion of urease- and uricase-containing,indole- and p-cresol-forming and contraction of short-chain fatty acid-producing intestinal microbiota in ESRD［J］.American journal of nephrology,2014,39(3):230-237.

［482］Felizardo R J,Castoldi A,Andrade-Oliveira V,et al.The microbiota and chronic kidney diseases:a double-edged sword［J］.Clinical & translational immunology,2016,5(6):e86.

［483］Wang S,Lv D,Jiang S,et al.Quantitative reduction in short-chain fatty acids,especially butyrate,contributes to the progression of chronic kidney disease［J］.Clinical science (London,England:1979),2019,133(17):1857-1870.

［484］Knauf F,Brewer J R,Flavell R A.Immunity,microbiota and kidney disease［J］.Nature reviews Nephrology,2019,15(5):263-274.

［485］Lau W L,Chang Y,Vaziri N D.The consequences of altered microbiota in immune-related chronic kidney disease［J］.Nephrol Oial Trans Plant,2020 May 21; gf aa087.

［486］Mazmanian S K,Liu C H,Tzianabos A O,et al.An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system［J］.Cell,2005,122(1):107-118.

［487］Ochoa-Repáraz J,Mielcarz D W,Ditrio L E,et al.Central nervous system demyelinating disease protection by the human commensal Bacteroides fragilis depends on polysaccharide A expression［J］.Journal of immunology (Baltimore,Md:1950),2010,185(7):4101-4108.

［488］Dasgupta S,Erturk-Hasdemir D,Ochoa-Reparaz J,et al.Plasmacytoid dendritic cells mediate antiinflammatory responses to a gut commensal molecule via both innate and adaptive mechanisms［J］.Cell host & microbe,2014,15(4):413-423.

［489］An D,Oh S F,Olszak T,et al.Sphingolipids from a symbiotic microbe regulate homeostasis of host intestinal natural killer T cells［J］.Cell,2014,156(1-2):123-133.

［490］Furusawa Y,Obata Y,Fukuda S,et al.Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells［J］.Nature,2013,504(7480):446-450.

［491］Park J,Kim M,Kang S G,et al.Short-chain fatty acids induce both effector and regulatory T cells by suppression of histone deacetylases and regulation of the mTOR-S6K pathway［J］.Mucosal immunology,2015,8(1):80-93.

［492］Hori S,Nomura T,Sakaguchi S.Control of regulatory T cell development by the transcription factor Foxp3［J］.Science (New York,NY),2003,299(5609):1057-1061.

［493］Wilck N,Matus M G,Kearney S M,et al.Salt-responsive gut commensal modulates T(H)17 axis and disease［J］.Nature,2017,551(7682):585-589.

［494］Yan J,Herzog J W,Tsang K,et al.Gut microbiota induce IGF-1 and promote bone formation and growth［J］.Proceedings of the National Academy of Sciences of the United States of America,2016,113(47):E7554-e7563.

［495］Josefsdottir K S,Baldridge M T,Kadmon C S,et al.Antibiotics impair murine hematopoiesis by depleting the intestinal microbiota［J］.Blood,2017,129(6):729-739.

［496］Barbieri C,Molina M,Ponce P,et al.An international observational study suggests that artificial intelligence for clinical decision support optimizes anemia management in hemodialysis patients［J］.Kidney international,2016,90(2):422-429.

［497］Hingorani S,Gooley T,Pao E,et al.Urinary cytokines after HCT:evidence for renal inflammation in the pathogenesis of proteinuria and kidney disease［J］.Bone marrow transplantation,2014,49(3):403-409.

［498］Zhao Y Y,Wang H L,Cheng X L,et al.Metabolomics analysis reveals the association between lipid abnormalities and oxidative stress,inflammation,fibrosis,and Nrf 2 dysfunction in aristolochic acidinduced nephropathy［J］.Scientific Reports,2015(5):12936.

［499］Chen D Q,Chen H,Chen L,et al.The link between phenotype and fatty acid metabolism in advanced chronic kidney disease［J］.Nephrology,dialysis,transplantation:official publication of the European Dialysis and Transplant Association - European Renal Association,2017,32(7):1154-1166.

［500］Vaziri N D,Goshtasbi N,Yuan J,et al.Uremic plasma impairs barrier function and depletes the tight junction protein constituents of intestinal epithelium［J］.American journal of nephrology,2012,36(5):438-443.

［501］Vaziri N D,Yuan J,Norris K.Role of urea in intestinal barrier dysfunction and disruption of epithelial tight junction in chronic kidney disease［J］.American journal of nephrology,2013,37(1):1-6.

［502］Kim S,Goel R,Kumar A,et al.Imbalance of gut microbiome and intestinal epithelial barrier dysfunction in patients with high blood pressure［J］.Clinical science (London,England:1979),2018,132(6):701-718.

［503］Santisteban M M,Qi Y,Zubcevic J,et al.Hypertension-Linked Pathophysiological Alterations in the Gut［J］.Circulation research,2017,120(2):312-323.

［504］Omenetti S,Pizarro T T.The Treg/Th17 Axis:A Dynamic Balance Regulated by the Gut Microbiome［J］.Frontiers in immunology,2015(6):639.

［505］Baccarelli A,Rienstra M,Benjamin E J.Cardiovascular epigenetics:basic concepts and results from animal and human studies［J］.Circulation Cardiovascular genetics,2010,3(6):567-573.

［506］Liang M,Cowley A W,Jr.,Mattson D L,et al.Epigenomics of hypertension［J］.Seminars in nephrology,2013,33(4):392-399.

［507］Kotchen T A,Cowley A W,Jr.,Liang M.Ushering Hypertension Into a New Era of Precision Medicine［J］.Jama,2016,315(4):343-344.

［508］Li LX,Agborbesong E,Zhang L,et al.Investigation of epigenetics in kidney cell biology［J］.Methods in cell biology,2019(153):255-278.

［509］Liu P,Liu Y,Liu H,et al.Role of DNA De Novo ( De )Methylation in the Kidney in Salt-Induced Hypertension［J］.Hypertension ( Dallas,Tex:1979 ),2018,72(5):1160-1171.

［510］Miyoshi M,Sato M,Saito K,et al.Maternal Protein Restriction Alters the Renal Ptger1 DNA Methylation State in SHRSP Offspring［J］.Nutrients,2018,10(10):1436.

［511］Dasinger J H,Alsheikh A J,Abais-Battad J M,et al.Epigenetic Modifications in T Cells:The Role of DNA Methylation in Salt-Sensitive Hypertension［J］.Hypertension ( Dallas,Tex:1979 ),2020,75(2):372-382.

［512］Wing M R,Devaney J M,Joffe M M,et al.DNA methylation profile associated with rapid decline in kidney function:findings from the CRIC study［J］.Nephrology,dialysis,transplantation:official publication of the European Dialysis and Transplant Association-European Renal Association,2014,29(4):864-872.

［513］Wang C A,Drasin D,Pham C,et al.Homeoprotein Six2 promotes breast cancer metastasis via transcriptional and epigenetic control of E-cadherin expression［J］.Cancer research,2014,74(24):7357-7370.

［514］Li S Y,Park J,Guan Y,et al.DNMT1 in Six2 Progenitor Cells Is Essential for Transposable Element Silencing and Kidney Development［J］.Journal of the American Society of Nephrology:JASN,2019,30(4):594-609.

［515］Pushpakumar S,Kundu S,Narayanan N,et al.DNA hypermethylation in hyperhomocysteinemia contributes to abnormal extracellular matrix metabolism in the kidney［J］.FASEB journal:official publication of the Federation of American Societies for Experimental Biology,2015,29(11):4713-4725.

［516］Haberland M,Montgomery R L,Olson E N.The many roles of histone deacetylases in development and physiology:implications for disease and therapy［J］.Nature reviews Genetics,2009,10(1):32-42.

［517］Sterner D E,Berger S L.Acetylation of histones and transcription-related factors［J］.Microbiology and molecular biology reviews:MMBR,2000,64(2):435-459.

［518］Shimosawa T,Mu S,Shibata S,et al.The kidney and hypertension:pathogenesis of salt-sensitive hypertension［J］.Current hypertension reports,2012,14(5):468-472.

［519］Kahle K T,Ring A M,Lifton R P.Molecular physiology of the WNK kinases［J］.Annual review of physiology,2008,70:329-355.

［520］O’Reilly M,Marshall E,Macgillivray T,et al.Dietary electrolyte-driven responses in the renal WNK kinase pathway in vivo［J］.Journal of the American Society of Nephrology:JASN,2006,17(9):2402-2413.

［521］Mu S,Shimosawa T,Ogura S,et al.Epigenetic modulation of the renal β-adrenergic-WNK4 pathway in salt-sensitive hypertension［J］.Nature medicine,2011,17(5):573-580.

［522］Guo J,Wang Z,Wu J,et al.Endothelial SIRT6 Is Vital to Prevent Hypertension and Associated Cardiorenal Injury Through Targeting Nkx3.2-GATA5 Signaling［J］.Circulation research,2019,124(10):1448-1461.

［523］Muta K,Obata Y,Oka S,et al.Curcumin ameliorates nephrosclerosis via suppression of histone acetylation independent of hypertension［J］.Nephrology,dialysis,transplantation:official publication of the European Dialysis and Transplant Association-European Renal Association,2016,31(10):1615-1623.

［524］Wang C P,Yu T H,Wu C C,et al.Circulating secreted frizzled-related protein 5 and chronic kidney disease in patients with acute ST-segment elevation myocardial infarction［J］.Cytokine,2018(110):367-373.

［525］Tazoe H,Otomo Y,Karaki S,et al.Expression of short-chain fatty acid receptor GPR41 in the human colon［J］.Biomedical research (Tokyo,Japan),2009,30(3):149-156.

［526］Li L,Ma L,Fu P.Gut microbiota-derived short-chain fatty acids and kidney diseases［J］.Drug design,development and therapy,2017(11):3531-3542.

［527］Marques F Z,Booth S A,Charchar F J.The emerging role of non-coding RNA in essential hypertension and blood pressure regulation［J］.Journal of human hypertension,2015,29(8):459-467.

［528］Kato M,Arce L,Natarajan R.MicroRNAs and their role in progressive kidney diseases［J］.Clinical journal of the American Society of Nephrology:CJASN,2009,4(7):1255-1266.

［529］Trionfini P,Benigni A,Remuzzi G.MicroRNAs in kidney physiology and disease［J］.Nature reviews Nephrology,2015,11(1):23-33.

［530］Liu Y,Usa K,Wang F,et al.MicroRNA-214-3p in the Kidney Contributes to the Development of Hypertension［J］.Journal of the American Society of Nephrology:JASN,2018,29(10):2518-2528.

［531］Baker M A,Wang F,Liu Y,et al.MiR-192-5p in the Kidney Protects Against the Development of Hypertension［J］.Hypertension ( Dallas,Tex:1979),2019,73(2):399-406.

［532］Li X,Cai W,Xi W,et al.MicroRNA-31 Regulates Immunosuppression in Ang Ⅱ(Angiotensin Ⅱ)-induced Hypertension by Targeting Ppp6C ( Protein Phosphatase 6c )［J］.Hypertension ( Dallas,Tex:1979 ),2019,73(5):e14-e24.

［533］Shang F,Wang S C,Hsu C Y,et al.MicroRNA-92a Mediates Endothelial Dysfunction in CKD［J］.Journal of the American Society of Nephrology:JASN,2017,28(11):3251-3261.

［534］Weber gJ,Purkayastha B,Ren L,et al.Hypertension exaggerates renovascular resistance via miR-122-associated stress response in aging［J］.Journal of hypertension,2018,36(11):2226-2236.

［535］Klimczak D,Kuch M,Pilecki T,et al.Plasma microRNA-155-5p is increased among patients with chronic kidney disease and nocturnal hypertension［J］.Journal of the American Society of Hypertension:JASH,2017,11(12):831-841.e834.

［536］Lemley K V.Machine Learning Comes to Nephrology［J］.Journal of the American Society of Nephrology:JASN,2019,30(10):1780-1781.

［537］Bukowy J D,Dayton A,Cloutier D,et al.Region-Based Convolutional Neural Nets for Localization of Glomeruli in Trichrome-Stained Whole Kidney Sections［J］.Journal of the American Society of Nephrology:JASN,2018,29(8):2081-2088.

［538］Kolachalama V B,Singh P,Lin C Q,et al.Association of Pathological Fibrosis With Renal Survival Using Deep Neural Networks［J］.Kidney international reports,2018,3(2):464-475.

［539］Galloway C D,Valys A V,Shreibati J B,et al.Development and Validation of a Deep-Learning Model to Screen for Hyperkalemia From the Electrocardiogram［J］.JAMA cardiology,2019,4(5):428-436.

［540］Tomašev N,Glorot X,Rae J W,et al.A clinically Applicable Approach to continuous prediction of future acute kidney injury［J］.Nature,2019,572(7767):116-119.

［541］Huang C,Murugiah K,Mahajan S,et al.Enhancing the prediction of acute kidney injury risk after percutaneous coronary intervention using machine learning techniques:A retrospective cohort study［J］.PLoS medicine,2018,15(11):e1002703.

［542］Chen T,Li X,Li Y,et al.Prediction and Risk Stratification of Kidney Outcomes in IgA Nephropathy［J］.American journal of kidney diseases:the official journal of the National Kidney Foundation,2019,74(3):300-309.

［543］Liu X,Li N S,Lv L S,et al.A comparison of the performances of an artificial neural network and a regression model for GFR estimation［J］.American journal of kidney diseases:the official journal of the National Kidney Foundation,2013,62(6):1109-1115.

［544］Webster A C,Nagler E V,Morton R L,et al.Chronic Kidney Disease［J］.Lancet,2017,389(10075):1238-1252.

［545］侯凡凡，马志刚，梅长林，等.中国五省市自治区慢性肾脏病患者心血管疾病的患病率调查［J］.中华医学杂志，2005，85（7）：458-463.

［546］Tangri N,Kitsios gD,Inker L A,et al.Risk prediction models for patients with chronic kidney disease:a systematic review［J］.Ann Intern Med,2013(158):596-603.

［547］赵明辉，张露霞.中国肾脏疾病科学报告［M］.北京：科学出版社，2019.

［548］Fox C S,Muntner P,Chen A Y,et al.Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease:a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry［J］.Circulation,2010,121(3):357-365.

［549］Pasternak R C,Criqui M H,Benjamin E J,et al.Atherosclerotic vascular disease conference:writing groupⅠ:epidemiology［J］.Circulation,2004( 109):2605-2612.

［550］张健，张宇辉.多中心、前瞻性中国心力衰竭注册登记研究——病因、临床特点和治疗情况初步分析［J］.中国循环杂志，2015，30（5）：413-416.

［551］Wetmore J B,Mahnken J D,Rigler S K,et al.The prevalence of and factors associated with chronic atrial fibrillation in Medicare/Medicaid-eligible dialysis patients［J］.Kidney Int,2012,81(5):469-476.

［552］Goldstein B A,Arce C M,Hlatky M A,et al.Trends in the incidence of atrial fibrillation in older patients initiating dialysis in the United States［J］.Circulation,2012,126(19):2293-2301.

［553］ Rattazzi M,Bertacco E,Del Vecchio A,et al.Aortic valve calcification in chronic kidney disease［J］.Nephrol Dial Transplant,2013(28):2968-2976.

［554］Samad Z,Sivak J A,Phelan M,et al.Prevalence and outcomes of leftsided valvular heart disease associated with chronic kidney disease［J］.J Am Heart Assoc,2017,6(10):e006044.

［555］Perkovic V,Hunt D,Griffin S V,et al.Accelerated progression of calcific aortic stenosis in dialysis patients［J］.Nephron Clin Pract,2003,94(2):c40-c45.

［556］Saran R,Robinson B,Abbott K C,et al.US Renal Data System 2017 Annual Data Report:Epidemiology of Kidney Disease in the United States［J］.Am J Kidney Dis,2018,71(3 Suppl 1):A7.

［557］Levin N W,Hoenich N A.Consequences of hyperphosphatemia and elevated levels of the calciumphosphorus product in dialysis patients［J］.Curr Opin Nephrol Hypertens,2001,10(5):563-568.

［558］Merjanian R,Budoff M,Adler S,et al.Coronary artery,aortic wall,and valvular calcification in nondialyzed individuals with type 2 diabetes and renal disease［J］.Kidney Int,2003,64(1):263-271.

［559］Rattazzi M,Bertacco E,Del Vecchio A,et al.Aortic valve calcification in chronic kidney disease［J］.Nephrol Dial Transplant,2013,28(12):2968-2976.

［560］Marwick T H,Amann K,Bangalore S,et al.Chronic kidney disease and valvular heart disease:conclusions from a Kidney Disease:Improving Global Outcomes (KDIGO) Controversies Conference［J］.Kidney Int,2019,96(4):836-849.

［561］Urena P,Malergue M C,Goldfarb B,et al.Evolutive aortic stenosis in hemodialysis patients:analysis of risk factors［J］.Nephrologie.1999(4),20:217-225.

［562］Dad T,Sarnak M J.Pericarditis and Pericardial Effusions in End-Stage Renal Disease［J］.Semin Dial.2016;29(5):366-373.

［563］Zheng Y,Cai gY,Chen X M,et al.Prevalence,awareness,treatment,and control of hypertension in the non-dialysis chronic kidney disease patients［J］.Chinese medical journal(Engl),2013,126(12):2276-2280.

［564］Ganidagli S E,Altunoren O,Erken E,et al.The relation between hemoglobin variability and carotid intima-media thickness in chronic hemodialysis patients［J］.Int Urol Nephrol,2017,49(10):1859-1866.

［565］Polak J F,O’Leary D H.Carotid intima-media thickness as surrogate for and predictor of CVD［J］.Glob Heart,2016,11(3):295-312.

［566］Jovanovich A,Isakova T,Stubbs J.Microbiome and Cardiovascular Disease in CKD［J］.Clin J Am Soc Nephrol,2018,13(10):1598-1604.

［567］Gracia M,Betriu A,Martínez-Alonso M,et al,Predictors of subclinical atheromatosis progression over 2 years in patients with different stages of CKD［J］.Clin J Am Soc Nephrol,2016,11(2):287-296.

［568］Hruska K A.Vascular smooth muscle cells in the pathogenesis of vascular calcification［J］.Circ Res,2009,104(6):710-711.

［569］Schwarc U,Buzello M,Eitz E,et al.Morphology of coronary ather-oscleroticn lesions in patients with end-stage renal failure［J］.Nephrol Dial Transplant,2000,15(2):218-223.

［570］Oh J,Wunsch R,Turzer M,et al.Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure［J］.Circulation,2002,106(1):100-105.

［571］Kerr P G,Guerin A P.Arterial Calcification and Stiffness in Chronic Kidney Disease［J］.Clin Exp Pharmacol Physiol,2007 ,34(7):683-687.

［572］Liabeuf S,Okazaki H ,Desjardins L,et al.Vascular calcification inchronic kidney disease:are biomarkers useful for probing the pathobiology and the health risks of this process in the clinical scenario［J］.Nephrol Dial Transplant,2014,29(7):1275-1284.

［573］Shroff RC,McNair R,Figg N,et al.Dialysis accelcrates medial vascularcalcification in part by triggering smooth muscle cell apoptosis［J］.Circulation,2008,118(17):1748-1757.

［574］Ciceri P,Elli F,Brenna I,et al.Lanthanum prevents high phosphateinduced vascular calcification by preserving vascular smooth musclelineage markers［J］.Calcif Tissue Int,2013,92(6):521-530.

［575］Allison B R,Nobuyuki M,Jane M,et al.CKD,arterial calcification,atherosclerosis and bone health:Interrelationships and controversies［J］.Atherosclerosis,2018(278):49-59.

［576］Ashwin R,Luke C P,Anna M P,et al.Coronary microvascular dysfunction:a key step in the development of urinemic cardiomyopathy?［J］.Heart,2019,105(17):1302-1309.

［577］McClellan W M,Flanders W D,Langston R D,et al.Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals:a population-based study［J］.Journal of the American Society of Nephrology,2002,13(7):1928-1936.

［578］Astor B C,Arnett D K,Brown A,et al.Association of kidney function and hemoglobin with left ventricular morphology among African Americans:the Atherosclerosis Risk in Communities (ARIC) study［J］.American Journal of Kidney Disease,2004,43(5):836-845.

［579］Wang X L,Shapiro J I.Evolving concepts in the pathogenesis of uraemic cardiomyopathy［J］.Nat Rev Nephrol,2019,15(3):159-175.

［580］Amann K,Ritz E,Wiest G,et al.A role of parathyroid homone of the activation of cardiac fibroblasts in uremia［J］.J Am Soc Nephrol,1994(4):1814-1819.

［581］Julien T,Nancy C,Laura K,et al.Chronic Kidney Disease and the Pathophysiology of Valvular Heart Disease［J］.Can J Cardiol,2019,35(9):1195-1207.

［582］Ewen S,Mahfoud F,Lauder L,et al.Chronic Kidney Disease and the Pathophysiology of Valvular Heart Disease［J］.Internist (Berl),2020,61(4):368-374.

［583］Marwick T H,Amann K,Bangalore S,et al.Chronic kidney disease and valvular heart disease:conclusions from a Kidney Disease:Improving Global Outcomes (KDIGO) Controversies Conference［J］.Kidney International,2019,96(4):836-849.

［584］Rehman K A,Betancor J,Xu B,et al.Uremic pericarditis,pericardial effusion,and constrictive pericarditis in end-stage renal disease:Insights and pathophysiology［J］.Clinical Cardiology,2017,40(10):839-846.

［585］Lindsay J,Crawley I S,Callaway gM.Chronic constrictive pericarditis following uremic hemopericardium［J］.Mosby,1970,79(3):390-395.

［586］Sadjadi S A,Mashahdian A.Uremic pericarditis:a report of 30 cases and review of the literature［J］.Am J Case Rep,2015(16):169-173.

［587］Wu Y,Huxley R,Li L,et al.Prevalence,awareness,treatment,and control of hypertension in China:data from the China National Nutrition and Health Survey 2002［J］.Circulation,2008,118(25):2679-2686.

［588］Professional Committee on Hypertension of Chinese Medical Association,Chinese Hypertension League,Cardiology Branch of Chinese Medical Association.Chinese expert consensus on family blood pressure monitoring［J］.Chin Journal Hypertens,2012,20(6):525-529.

［589］Hypertension Branch of Chinese Geriatric Medical Association.Chinese expert consensus on the diagnosis and treatment of abnormal blood pressure fluctuation in the elderly［J］.Chin Journal Cardiovasc Med,2017,22(2):1-11.

［590］Franklin S S,Wilkinson I B,McEniery C M.Unusual hypertensive phenotypes:what is their significance? ［J］.Hypertension,2012,59(2):173-178.

［591］American Academy of Pediatrics Steering Committee on Quality Improvement and Management.Classifying recommendations for clinical practice guidelines［J］.Pediatrics,2004,114(3):874-877.

［592］National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents.The fourth report on the diagnosis,evaluation,and treatment of high blood pressure in children and adolescents［J］.Pediatrics,2004,114(2,suppl 4th Report):555-576.

［593］Morganti A.A comparative study on inter and intralaboratory reproducibility of renin measurement with a conventional enzymatic method and a new chemiluminescent assay of immunoreactive renin［J］.Journal Hypertens,2010,28(6):1307-1312.

［594］Burdick L,Airoldi F,Marana I,et al.Superiority of acceleration and acceleration time over pulsatility and resistance indices as screening tests for renal arterystenosis［J］.Journal Hypertens,1996,14(10):1229-1235.

［595］Mwipatayi B P,Beningfield S J,White L E,et al.A review of the current treatment of renal artery stenosis［J］.Eur J Vasc Endovasc Surg Off J Eur Soc Vasc Surg,2005,29(5):479-488.

［596］Wheatley K,Ives N,Gray R,et al.Revascularization versus medical therapy for renal-artery stenosis［J］.N Engl J Med,2009,361(20):1953-1962.

［597］Navar L G,Harrison-Bernard L M,Nishiyama A,et al.Regulation of intrarenal angiotensin Ⅱin hypertension［J］.Hypertension,2002(39):316-322.

［598］Te Riet L,van Esch J H M,Roks A J M,et al.Hypertension:reninangiotensin-aldosterone system alterations［J］.Circ Res,2015,116(6):960-975.

［599］Kobori H,Nangaku M,Navar L G,et al.The intrarenal renin-angiotensin system:from physiology to the pathobiology of hypertension and kidney disease［J］.Pharmacol Rev,2007,59(3):251-287.

［600］Shinzato T,Nakai S,Skiba T.Survival in long-term hemodialysis patients:results from annual survey of the Japanese Society for Dialysis Therapy［J］.Nephrol Dial Tranplantation,1997,12(5):884-888.

［601］Alijanian N,Naini A E,Shahidi S.The comparative evaluation of patients’ body dry weight under hemodialysis using two methods:Bioelectrical impedance analysis and conventional method［J］.Journal Res Med Sci,2012,17(10):923-927.

［602］顾景范，杜寿玢，郭长江.现代临床营养学［M］.2 版.北京：科学出版社，2009.

［603］葛可佑.中国营养师培训教材 ［M］.北京：人民卫生出版社，2005.

［604］全国卫生专业技术资格考试用书编写专家委员会.营养学 ［M］.北京：人民卫生出版社，2017.

［605］孙秀发，凌文华.临床营养学［M］.3 版.北京：科学出版社，2016.

［606］葛均波，徐永健，王辰.内科学［M］.9 版.北京：人民卫生出版社，2018.

［607］中国肥胖问题工作组.我国成人体重指数和腰围对相关疾病危险因素异常的预测价值：适宜体重和腰围切点的研究［J］.中华流行病学杂志，2020，23（1）：5-10.

［608］中国疾病预防控制中心营养与健康.中国食物成分表［M］.北京：北京大学医学出版社，2018.

［609］Seccia T M,Caroccia B,Calò L A.Hypertensive nephropathy.Moving from classic to emerging pathogenetic mechanisms［J］.Journal Hypertens,2017,35(2):205-212.

［610］Paula Bricarello L,Poltronieri F,Fernandes R,et al.Effects of the Dietary Approach to Stop Hypertension (DASH) diet on blood pressure,overweight and obesity in adolescents:A systematic review ［J］.Clin Nutr ESPEN,2018(28):1-11.

［611］Cederholm T,Jensen gL,Correia MITD,et al.GLIM criteria for the diagnosis of malnutrition-A consensus report from the global clinical nutrition community ［J］.Clin Nutr,2019,38(1):1-9.

［612］Hart P D,Bakris gL.Hypertensive Nephropathy:prevention and treatment recommendations ［J］.Expert Opin Pharmacother,2010,11(16):2675-2686.

［613］Ikizler T A,Cano N J,Franch H,et al.Prevention and treatment of protein energy wasting in chronic kidney disease patients:a consensus statement by the International Society of Renal Nutrition and Metabolism［J］.Kidney Int,2013,84(6):1096-1107.

［614］Kovesdy C P,Kopple J D,Kalantar-Zadeh K.Management of protein-energy wasting in non-dialysisdependent chronic kidney disease:reconciling low protein intake with nutritional therapy［J］.Am J Clin Nutr,2013,97(6):1163-1177.

［615］Zhou M,Wang H,Zeng X,et al.Mortality,morbidity,and risk factors in China and its provinces,1990-2017:a systematic analysis for the Global Burden of Disease Study 2017［J］.Lancet,2019,394(10204):1145-1158.

［616］郑晶.维持性血液透析患者体力活动及其影响因素［D］.广州：中山大学，2009.

［617］Roshanravan B,Gamboa J,Wilund K,et al.Exercise and CKD:skeletal muscle dysfunction and practical application of exercise to prevent and treat physical impairments in CKD［J］.Am Journal Kidney Dis,2017,69(6):837-852.

［618］Koufaki P,Greenwood S,Painter P,et al.The bases expert statement on exercise therapy for people with chronic kidney disease［J］.Journal Sports Sci,2015,33(18):1902-1907.

［619］张雅玲，郝文亭.运动处方的制定与应用［J］.中国学校卫生，2005，26（6）：484-485.

［620］Piercy K L,Troiano R P,Ballard R M,et al.The Physical Activity Guidelines for Americans［J］.JAMA,2018,320(19):2020-2028.

［621］Arnett D K,Blumenthal R S,Albert M A,et al.2019 ACC/AHA Guideline on the primary prevention of cardiovascular disease:a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines［J］.Journal Am Coll Cardiol,2019,74(10):e177-232.

［622］季丽娜，曹力，陈大坤.慢性肾脏疾病运动康复治疗的研究进展［J］.中华肾脏病杂志，2006，22（8）：510-512.

［623］张悦，叶志斌，吴兆龙.运动致急性肾功能衰竭二例［J］.中华肾脏病杂志，2005，21（6）：314.

［624］Johansen K L,Painter P,et al.Exercise in individuals with CKD［J］.Am Journal Kidney Dis,2012,59(1)):126-134.

［625］Roshanravan B,Gamboa J,Wilund K,et al.Exercise and CKD:skeletal muscle dysfunction and practical Application of exercise to prevent and treat physical impairments in CKD［J］.Am Journal Kidney Dis,2017,69(6):837-852.

［626］其其格，赵建荣.慢性肾脏病的运动疗法［J］.医学综述，2017，23（13）：81-85.

［627］Pescatello L S,Franklin B A,Fagard R,et al.American college of sports medicine position stand exercise and hypertension［J］.Med Sci Sports Exerc,2004,36(3):533.

［628］Thompson P D,Arena R,Riebe D,et al.ACSM’s new preparticipation health screening recommendations from ACSM’s guidelines for exercise testing and prescription［J］.9th.Curr Sports Med Rep,2013,12(4):215-217.

［629］Ginty A T,Carroll D,Roseboom T J,et al.Depression and anxiety are associated with a diagnosis of hypertension 5 years later in a cohort of late middle-aged men and women［J］.Journal Hum Hypertens,2013,27(3):187-190.

［630］Sandström Y K,Ljunggren G,Wändell P,et al.Psychiatric comorbidities in patients with hypertension--a study of registered diagnoses 2009-2013 in the total population in Stockholm County,Sweden［J］.Journal Hypertens,2016,34(3):414-420.

［631］Bautista L E,Vera-Cala L M,Colombo C,et al.Symptoms of depression and anxiety and adherence to antihypertensive medication［J］.Am Journal Hypertens,2012,25(4):505-511.

［632］黄其峰，王伦善，贾建安，等.尿微量白蛋白、血清胱抑素C和血清同型半胱氨酸联合检测在早期高血压肾病的诊断价值［J］.安徽医药，2015，19（7）：1361-1362.

［633］苏海燕，蒋敏.阿托伐他汀联合缬沙坦和依那普利治疗高血压肾病的临床疗效分析［J］.内科急危重症杂志，2015，21（2）：122-124.

［634］Aider L,Peretz T,Hadani P E,et al.Psychological intervention in cancer patients:A randomized study［J］.General Hospital Psychiatry,2011,23(5):272-277.

［635］赵东江，李胜婷.心理支持疗法对口腔疾病患者应激反应的影响［J］.中国口腔医学杂志，2004，20（5）：662-664.

［636］仲海峰，韩晓骏，申宜梅.心理干预对慢性肾脏病患者焦虑/抑郁症状和生活质量的影响［J］.临床心身疾病杂志，2015，21（12）：1672-1687.

［637］龚豪，黄丽，张庆红，等.高血压肾病患者症状困扰与心理弹性和应对方式的相关性［J］.中国健康心理学杂志，2019，27（1）：2096-4811.

［638］赵军，孟丽霞，张柳青，等.慢性肾脏病患者的焦虑抑郁心理状态的护理干预措施［J］.国际精神病学杂志，2016，43（4）：1673-2952.

［639］Huang T,Larsen K T,Ried-Larsen M,et al.The effects of physicalactivity and exercise on brainderived neurotrophic factor inhealthy humans:A review［J］.Scand J Med Sci Sports,2014,24(1):1-10.

［640］Williams B,Mancia G,Spiering W,et al.2018 ESC/ESH Guidelines for the management of arterial hypertension:The Task Force for the Management Of Arterial Hypertension of the European Society of Cardiology and the European Society of Hypertension［J］.Journal Hypertens,2018,36(10):1953-2041.

［641］Whelton P K,Carey R M,Aronow W S,et al.2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/ NMA/PCNA Guideline for the prevention,detection,evaluation,and management of high blood pressure in adults:a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines［J］.Hypertension,2018,71(6):1269-1324.

［642］James P A,Oparil S,Carter B L,et al.2014 evidence-based guideline for the management of high blood pressure in adults:report from the panel members Appointed to the Eighth Joint National Committee (JNC 8)［J］.Jama,2014,311(5):507-520.

［643］Mancia G,Fagard R,Narkiewicz K,et al.2013 ESH/ESC guidelines for the management of arterial hypertension:the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)［J］.European Heart Journal,2013,34(28):2159-2219.

［644］Wright J T Jr,Williamson J D,Whelton P K,et al.A randomized trial of intensive versus standard blood-pressure control.SPRINT Research Group［J］.N Engl Journal Med,2015,373(22):2103-2116.

［645］Cushman W C,Evans gW,Byington R P,et al.Effects of intensive blood-pressure control in type 2 diabetes mellitus.ACCORD Study Group［J］.N Engl Journal Med,2010,362(17):1575-1585.

［646］Goff D C Jr,Lloyd-Jones D M,Bennett G,et al.2013 ACC/AHA guideline on the assessment of cardiovascular risk:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines［J］.Circulation,2014,129(suppl 2):S49-S73.

［647］Peterson J C,Adler S,Burkart J M,et al.Blood pressure control,proteinuria,and the progression of renal disease.The Modification of Diet in Renal Disease Study［J］.Ann Intern Med,1995,123:754-762.

［648］Mancia G,Fagard R,Narkiewicz K,et al.2013 ESH/ESC guidelines for the management of arterial hypertension:the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)［J］.Eur Heart J,2013,34(28):2159-2219.

［649］Lurbe E,Agabiti-Rosei E,Cruickshank J K,et al.2016 European Society of Hypertension Guidelines for the management of high blood pressure in children and adolescents［J］.Journal Hypertens,2016,34(10):1887-1920.

［650］National Kidney Foundation.K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease［J］.Am Journal Kidney Dis,2004,43(5 Suppl 1):S1-S290.

［651］National Kidney Foundation.K/DOQI clinical practice guidelines for chronic kidney disease:evaluation,classification,and stratification.Am J Kidney Dis,2002,39(2 Suppl 1):S1-S266.

［652］Kidney Disease:Improving Global Outcomes (KDIGO) Blood Pressure Work Group.KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease［J］.Kidney Int Suppl,2012(2):337-414.

［653］Dionne J M.Evidence-based guidelines for the management of hypertension in children with chronic kidney disease［J］.Pediatr Nephrol,2015,30(11):1919-1927.

［654］Lurbe E,Agabiti-Rosei E,Cruickshank J K,et al.2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents［J］.Journal Hypertens,2016,34(10):1887-1920.

［655］Flynn J T,Kaelber D C,Baker-Smith C M,et al.Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents［J］.Pediatrics,2017,140(3):e2017190.

［656］Nerenberg K A,Zarnke K B,Leung A A,et al.Hypertension Canada’s 2018 Guidelines for Diagnosis,Risk Assessment,Prevention,and Treatment of Hypertension in Adults and Children［J］.Can Journal Cardiol,2018,34(5):506-525.

［657］Benetos A,Bulpitt C J,Petrovic M,et al.An Expert Opinion From the European Society of Hypertension-European Union Geriatric Medicine Society Working Group on the Management of Hypertension in Very Old,Frail Subjects［J］.Hypertension,2016,67(5):820-825.

［658］Kjeldsen S E,Stenehjem A,Os I,et al.Treatment of high blood pressure in elderly and octogenarians:European Society of Hypertension statement on blood pressure targets［J］.Blood Press,2016,25(6):333-336.

［659］中国老年医学学会高血压分会.中国老年高血压管理指南［J］.中华老年多器官疾病杂志，2019，18（2）：81-106.

［660］高血压联盟（中国）.中国高血压防治指南 2018年修订版［J］.心脑血管病防治，2019，19（1）：1-44.

［661］Qaseem A,Wilt T J,Rich R,et al.Pharmacologic Treatment of Hypertension in Adults Aged 60 Years or Older to Higher Versus Lower Blood Pressure Targets:A clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians［J］.Ann Intern Med,2017,166(6):430-437.

［662］Unger T,Borghi C,Charchar F,et al.2020 International Society of Hypertension Global Hypertension Practice Guidelines［J］.Hypertension,2020,75(6):1334-1357.

［663］Dionne J M.Evidence-based guidelines for the management of hypertension in children with chronic kidney disease［J］.Pediatr Nephrol.2015,30(11):1919-1927.

［664］Wheeler D C,Becker gJ.Summary of KDIGO guideline.What do we really know about management of blood pressure in patients with chronic kidney disease? ［J］.Kidney International,2013,83(3):377-383.

［665］Cheung A K,Chang T I,Cushman W C,et al.Blood pressure in chronic kidney disease:conclusions from a Kidney Disease:Improving Global Outcomes (KDIGO) Controversies Conference.Conference Participants［J］.Kidney Int,2019,95(5):1027-1036.

［666］Castillo-Rodriguez E,Fernandez-Fernandez B,Alegre-Bellassai R,et al.The chaos of hypertension guidelines for chronic kidney disease patients［J］.Clin Kidney Journal,2019,12(6):771-777.

［667］Georgianos P I,Vaios V,Zebekakis P E,et al.Blood pressure targets in patients with chronic kid ney disease:A critical evaluation of clinical-trial evidence and guideline recommendations［J］.Journal Clin Hypertens (Greenwich),2020,22(5):924-928.

［668］Guerrot D,Humalda J K.Blood pressure targets in chronic kidney disease:an update on the evidence［J］.Current Opinion in Nephrology Hypertens,2020,29(3):327-332.